In		O
this		O
work		O
,		O
to		O
evaluate		O
the		O
relative		O
free		O
energies		O
of		O
hydration		O
and		O
binding		O
to		O
thrombin		O
for		O
some		O
benzamidine		O
derivatives		O
,		O
we		O
used		O
the		O
finite		O
difference		O
thermodynamic		O
integration		O
(		O
FDTI		O
)		O
algorithm		O
within		O
the		O
Discover		O
program		O
of		O
MSI		O
.		O
The		O
acids		O
were		O
coupled		O
with		O
diethyl		O
glutamate		O
,		O
followed		O
by		O
saponification		O
,		O
to		O
give		O
the		O
10		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
8,10		I-IUPAC
-		I-IUPAC
dideazaminopterins		I-IUPAC
.		O
Structure		O
-		O
activity		O
analysis		O
at		O
adenosine		O
receptors		O
indicated		O
that		O
pyridyl		O
,		O
furyl		O
,		O
benzofuryl		O
,		O
and		O
thienyl		O
groups		O
at		O
the		O
4		O
-		O
position		O
resulted		O
in		O
,		O
at		O
most		O
,		O
only		O
moderate		O
selectivity		O
for		O
A3		O
adenosine		O
receptors		O
.		O
The		O
target		O
compounds		O
9-12		O
were		O
obtained		O
by		O
an		O
N1		O
regioselective		O
intramolecular		O
cyclization		O
reaction		O
of		O
silylated		O
5-8		O
using		O
trimethylsilyl		O
trifluoromethanesulfonate		O
(		O
TMS		O
triflate		O
)		O
as		O
the		O
catalyst		O
.		O
Saponification		O
of		O
the		O
antifolate		O
esters		O
so		O
produced		O
gave		O
the		O
desired		O
analogues		O
.		O
13,24		B-IUPAC
-		I-IUPAC
Cyclo		I-IUPAC
-		I-IUPAC
18,21		I-IUPAC
-		I-IUPAC
dinorcholanes		I-IUPAC
containing		O
a		O
ketone		O
or		O
conjugated		O
ketone		O
group		O
at		O
C		O
-		O
20		O
,		O
C		O
-		O
22		O
,		O
C		O
-		O
23		O
,		O
or		O
C		O
-		O
24		O
were		O
prepared		O
as		O
conformationally		O
constrained		O
analogues		O
of		O
these		O
anesthetic		O
steroids		O
and		O
were		O
used		O
to		O
probe		O
for		O
alternate		O
locations		O
for		O
the		O
D		O
-		O
ring		O
hydrogen		O
-		O
bond		O
-		O
accepting		O
carbonyl		B-IUPAC
group		B-MODIFIER
.		O
We		O
propose		O
that		O
neonicotinoids		O
with		O
a		O
protonated		O
N		O
-		O
unsubstituted		O
imine		O
or		O
equivalent		O
substituent		O
recognize		O
the		O
anionic		O
subsite		O
of		O
the		O
mammalian		O
alpha4beta2		O
nAChR		O
whereas		O
the		O
negatively		O
charged		O
(		O
delta		O
(		O
-		O
)		O
)		O
tip		O
of		O
the		O
neonicotinoid		O
insecticides		O
interacts		O
with		O
a		O
putative		O
cationic		O
subsite		O
of		O
the		O
insect		O
nAChR		O
.		O
The		O
best		O
calpain		O
I		O
inhibitor		O
in		O
this		O
study		O
was		O
Z		O
-		O
Leu		O
-		O
Nva		O
-		O
CONH		O
-		O
CH2		O
-		O
2		O
-		O
pyridyl		O
(		O
Ki		O
=		O
19		O
nM		O
)		O
.		O
Thymidylate		O
synthase		O
inhibition		O
was		O
studied		O
with		O
two		O
forms		O
of		O
the		O
enzyme		O
differing		O
in		O
sensitivities		O
toward		O
5		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
monophosphate		I-IUPAC
(		O
FdUMP		O
)		O
,		O
isolated		O
from		O
parental		O
and		O
FdUrd		O
-		O
resistant		O
L1210		O
cell		O
lines		O
.		O
A		O
comparison		O
of		O
the		O
PNMT		O
inhibitory		O
potency		O
of		O
the		O
enantiomers		O
of		O
these		O
3		B-PARTIUPAC
-		I-PARTIUPAC
fluoromethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
hydroxymethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
chloromethyl		I-IUPAC
-		I-IUPAC
THIQs		I-IUPAC
indicates		O
that		O
all		O
of		O
the		O
3		O
-		O
substituted		O
-		O
THIQs		O
displayed		O
similar		O
inhibitory		O
potency		O
for		O
PNMT		O
.		O
These		O
compounds		O
behave		O
as		O
potent		O
antagonists		O
of		O
the		O
Grb2		O
-		O
Shc		O
interaction		O
.		O
This		O
mixture		O
was		O
rearranged		O
by		O
heating		O
with		O
molecular		O
sieve		O
in		O
refluxing		O
toluene		O
to		O
give		O
a		O
6		O
:		O
1		O
mixture		O
of		O
2		O
and		O
3		O
.		O
The		O
5		O
-		O
isoxazolol		O
isomer		O
of		O
10		O
,		O
compound		O
12		O
,		O
showed		O
a		O
reduced		O
receptor		O
affinity		O
(		O
IC50		O
=		O
26		O
+		O
/		O
-		O
7		O
microM		O
)		O
and		O
a		O
very		O
low		O
relative		O
efficacy		O
.		O
At		O
the		O
N		O
-		O
1		O
position		O
"		O
standard		O
"		O
substitution		O
was		O
employed		O
with		O
the		O
ethyl		B-IUPAC
,		O
cyclopropyl		B-IUPAC
,		O
and		O
p		B-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
groups		B-MODIFIER
being		O
used		O
.		O
A		O
potential		O
H		O
-		O
bonding		O
interaction		O
between		O
the		O
pyridyl		O
nitrogen		O
free		O
electron		O
pair		O
and		O
the		O
suitably		O
positioned		O
1,4		B-IUPAC
-		I-IUPAC
dihydropyridine		I-IUPAC
NH		B-MODIFIER
moiety		I-MODIFIER
may		O
stablize		O
this		O
rotamer		O
orientation		O
.		O
Affinity		O
was		O
determined		O
in		O
radioligand		O
binding		O
assays		O
at		O
rat		O
brain		O
A1		O
and		O
A2A		O
receptors		O
using		O
[		O
3H		O
]		O
-		O
(		O
R		O
)		O
-		O
PIA		O
(		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylisopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
adenosine		I-IUPAC
)		O
and		O
[		O
3H		O
]		O
CGS		O
21680		O
(		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
ethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
ethylaminol		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
carbamoyl		I-IUPAC
)		I-IUPAC
adenosine		I-IUPAC
)		O
,		O
respectively		O
.		O
Hydrolysis		O
of		O
2,4		B-IUPAC
-		I-IUPAC
dichloroquinazoline		I-IUPAC
to		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
quinazolinol		I-IUPAC
was		O
followed		O
by		O
condensation		O
with		O
the		O
appropriate		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dialkylalkylenediamine		I-IUPAC
to		O
give		O
an		O
array		O
of		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
dialkylamino		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
quinazolinols		I-IUPAC
(		O
IXa		O
)		O
.		O
It		O
was		O
more		O
potent		O
than		O
,		O
and		O
equally		O
efficacious		O
to		O
,		O
L		O
-		O
glutamate		O
in		O
[		O
3H		O
]		O
MK801		O
binding		O
.		O
These		O
findings		O
motivated		O
us		O
to		O
search		O
for		O
the		O
preparation		O
of		O
new		O
selective		O
radioligands		O
for		O
the		O
A		O
(		O
3		O
)		O
subtype		O
;		O
hence		O
,		O
a		O
procedure		O
to		O
introduce		O
a		O
tritiated		O
alkylamino		O
group		O
in		O
these		O
molecules		O
was		O
carried		O
out		O
.		O
Compound		O
6		O
,		O
but		O
not		O
7		O
,		O
proved		O
to		O
be		O
a		O
very		O
potent		O
agonist		O
(		O
EC		O
(		O
50		O
)		O
=		O
0.13		O
microM		O
)		O
at		O
the		O
kainate		O
-		O
preferring		O
GluR5		O
subunit		O
,		O
equipotent		O
with		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyisothiazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
[		O
(		O
S		O
)		O
-		O
Thio		O
-		O
ATPA		O
,		O
4		O
]		O
and		O
almost		O
4		O
times		O
more		O
potent		O
than		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
[		O
(		O
S		O
)		O
-		O
ATPA		O
,		O
3		O
]		O
.		O
Four		O
selected		O
acronycine		O
derivatives		O
(		O
17,19		O
,		O
21		O
,		O
and		O
22		O
)		O
were		O
evaluated		O
in		O
vivo		O
against		O
murine		O
P388		O
leukemia		O
and		O
colon		O
38		O
adenocarcinoma		O
implanted		O
in		O
mice		O
.		O
Potent		O
delta		O
-		O
agonists		O
and		O
bifunctional		O
compounds		O
with		O
high		O
delta		O
-		O
and		O
mu		O
-		O
opioid		O
receptor		O
affinities		O
were		O
obtained		O
by		O
varying		O
the		O
spacer		O
length		O
[		O
none		O
,		O
NH		O
-		O
CH		O
(		O
2		O
)		O
,		O
NH		O
-		O
CH		O
(		O
2		O
)		O
-		O
CH		O
(		O
2		O
)		O
,		O
Gly		O
-		O
NH		O
-		O
CH		O
(		O
2		O
)		O
]		O
and		O
C		O
-		O
terminal		O
aromatic		O
nucleus		O
[		O
1H		B-PARTIUPAC
-		I-PARTIUPAC
benzimidazole		I-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
yl		I-PARTIUPAC
,		O
phenyl		B-PARTIUPAC
(		O
Ph		O
)		O
and		O
benzyl		B-IUPAC
groups		B-MODIFIER
]		O
.		O
Alkenes		O
4d		O
and		O
4e		O
were		O
cyclized		O
to		O
heterocycles		O
12		O
and		O
13		O
.		O
However		O
,		O
its		O
clinical		O
potential		O
is		O
limited		O
by		O
acute		O
toxicity		O
of		O
the		O
free		O
ligand		O
(		O
but		O
not		O
Fe3+		O
complex		O
)		O
at		O
high		O
dosage		O
.		O
In		O
addition		O
,		O
2a		O
possesses		O
a		O
carbomethoxy		O
substituent		O
adjacent		O
to		O
the		O
aryl		O
ring		O
,		O
whereas		O
(		O
3S		O
,		O
4R		O
)		O
-		O
3		O
contains		O
a		O
[		B-IUPAC
3,4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylenedioxy		I-IUPAC
)		I-IUPAC
phenoxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
.		O
In		O
the		O
catalytic		O
hydrogenation		O
of		O
10		B-IUPAC
-		I-IUPAC
ethoxalylfolic		I-IUPAC
acid		I-IUPAC
(		O
5		O
)		O
,		O
the		O
initial		O
product		O
10		O
-		O
(		O
EtO2CCO		O
)		O
-		O
THF		O
(		O
22		O
)		O
rearranged		O
readily		O
to		O
give		O
5		O
-		O
(		O
EtO2CCO		O
)		O
-		O
THF		O
(		O
21		O
)		O
.		O
This		O
leads		O
to		O
the		O
formation		O
of		O
a		O
2		B-IUPAC
-		I-IUPAC
hydroxyoxazaphosphorine		I-IUPAC
ring		O
with		O
R		O
=		O
H		O
(		O
3a		O
coming		O
from		O
compounds		O
2a		O
,		O
c		O
)		O
or		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
2		O
)		O
Cl		O
(		O
3b		O
coming		O
from		O
compounds		O
2b		O
,		O
d		O
)		O
and		O
to		O
the		O
release		O
of		O
ammonia		O
or		O
chloroethylamine		O
.		O
The		O
results		O
of		O
this		O
study		O
indicate		O
that		O
MTX		O
and		O
DCM		O
esters		O
are		O
not		O
therapeutically		O
equivalent		O
in		O
mice		O
,		O
despite		O
the		O
high		O
serum		O
esterase		O
activity		O
in		O
this		O
species		O
,		O
and		O
that		O
an		O
up		O
to		O
10		O
-		O
fold		O
reduction		O
in		O
total		O
administered		O
dose		O
on		O
the		O
q3dX3		O
schedule		O
is		O
feasible		O
by		O
this		O
approach		O
.		O
Treatment		O
of		O
5		O
with		O
mercuric		O
chloride		O
furnished		O
the		O
toyocamycin		O
analogue		O
7		O
.		O
The		O
amine		O
4		O
shows		O
about		O
7		O
-		O
fold		O
lower		O
affinity		O
than		O
DA		O
for		O
both		O
sites		O
and		O
is		O
not		O
able		O
to		O
discriminate		O
between		O
the		O
two		O
subtypes		O
of		O
DA		O
receptors		O
.		O
Compound		O
9		O
,		O
in		O
which		O
a		O
phenolic		O
group		O
is		O
in		O
the		O
same		O
region		O
of		O
space		O
as		O
the		O
acidic		O
NH		O
of		O
1		O
,		O
exhibited		O
the		O
best		O
alpha		O
2		O
-		O
adrenoceptor		O
affinity		O
of		O
any		O
of		O
the		O
compounds		O
studied		O
(		O
PNMT		O
Ki		O
=		O
0.98		O
microM		O
,		O
alpha		O
2		O
Ki		O
=		O
0.078		O
microM		O
,		O
selectivity		O
=		O
0.080		O
)		O
.		O
Interestingly		O
,		O
methoxyethoxy		O
(		O
IC		O
(		O
50		O
)		O
of		O
16j		O
is		O
0.02		O
microM		O
;		O
IC		O
(		O
50		O
)		O
of		O
17h		O
is		O
0.01		O
microM		O
)		O
and		O
ethoxyethoxy		O
(		O
IC		O
(		O
50		O
)		O
of		O
17j		O
is		O
0.02		O
micro		O
M		O
)		O
analogues		O
showed		O
the		O
most		O
potent		O
activity		O
,		O
suggesting		O
that		O
the		O
inserted		O
oxygen		O
atom		O
significantly		O
interacts		O
with		O
beta		O
-		O
PDGFR		O
.		O
Reductive		O
alkylation		O
of		O
THF		O
with		O
glyoxylic		O
acid		O
and		O
5		B-IUPAC
-		I-IUPAC
hydroxypentanal		I-IUPAC
,		O
respectively		O
,		O
gave		O
5		O
-		O
(		O
HO2CCH2		O
)		O
-		O
THF		O
(		O
24		O
)		O
and		O
5		O
-		O
[		O
HO		O
(		O
CH2		O
)		O
5		O
]		O
-		O
THF		O
(		O
25		O
)		O
.		O
ATP		O
2		O
-		O
thioethers		O
displayed		O
pD2		O
values		O
in		O
the		O
range		O
of		O
6-8		O
in		O
smooth		O
muscle		O
assay		O
systems		O
for		O
activity		O
at		O
P2Y		O
-		O
receptors		O
.		O
All		O
of		O
the		O
isozymes		O
tested		O
possessed		O
measurable		O
activity		O
with		O
phenethyl		O
chloride		O
.		O
Thf2		O
-		O
FU		O
was		O
found		O
to		O
be		O
effective		O
against		O
murine		O
solid		O
tumors		O
and		O
it		O
was		O
less		O
toxic		O
than		O
Thf		O
-		O
FU		O
when		O
given		O
orally		O
.		O
The		O
dedifferentiation		O
agent		O
"		O
reversine		O
"		O
[		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
morpholinoanilino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyclohexyladenine		I-IUPAC
2		I-IUPAC
]		O
was		O
found		O
to		O
be		O
a		O
moderately		O
potent		O
antagonist		O
for		O
the		O
human		O
A		O
(		O
3		O
)		O
adenosine		O
receptor		O
(		O
AR		O
)		O
with		O
a		O
K		O
(		O
i		O
)		O
value		O
of		O
0.66		O
microM		O
.		O
In		O
contrast		O
to		O
the		O
parent		O
compound		O
ACPA		O
(		O
2		O
)		O
(		O
IC		O
(		O
50		O
)		O
=		O
6.3		O
microM		O
)		O
,		O
none		O
of		O
the		O
analogues		O
described		O
showed		O
detectable		O
inhibitory		O
effect		O
on		O
[		B-IUPAC
(		I-IUPAC
3		I-IUPAC
)		I-IUPAC
H		I-IUPAC
]		I-IUPAC
kainic		I-IUPAC
acid		I-IUPAC
receptor		O
binding		O
.		O
The		O
analog		O
was		O
purified		O
by		O
desalting		O
on		O
Sephadex		O
G		O
-		O
15		O
in		O
50%		O
HOAc		O
and		O
gel		O
filtration		O
on		O
Sephadex		O
G		O
-		O
25		O
and		O
LH		O
-		O
20		O
.		O
The		O
most		O
active		O
compound		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
12a		O
,		O
ID50		O
=		O
0.1		O
micrograms		O
/		O
mL		O
)		O
,		O
which		O
exhibited		O
antiviral		O
activity		O
(		O
HSV		O
-		O
1		O
)		O
100		O
-		O
fold		O
higher		O
than		O
that		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethyl		I-IUPAC
)		I-IUPAC
analogue		B-MODIFIER
(		O
11a		O
)		O
,		O
was		O
less		O
active		O
than		O
IVDU		O
or		O
acyclovir		O
(		O
ID50		O
=		O
0.01-0.1		O
micrograms		O
/		O
mL		O
range		O
)		O
.		O
These		O
were		O
8		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
O6		B-IUPAC
-		I-IUPAC
benzylguanines		I-IUPAC
bearing		O
electron		O
-		O
withdrawing		O
groups		O
at		O
the		O
8		O
-		O
position		O
(		O
e.g.		O
8		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
O6		I-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
and		O
O6		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
bromoguanine		I-IUPAC
)		O
and		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
pyrimidines		I-IUPAC
bearing		O
electron		O
-		O
withdrawing		O
groups		O
at		O
the		O
5		O
-		O
position		O
(		O
e.g.		O
2,4		B-PARTIUPAC
-		I-PARTIUPAC
diamino		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
benzyloxy		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
nitroso		I-PARTIUPAC
-		I-PARTIUPAC
and		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
nitropyrimidine		I-IUPAC
)		O
.		O
These		O
were		O
evaluated		O
in		O
human		O
foreskin		O
fibroblast		O
cells		O
challenged		O
with		O
the		O
vaccinia		O
virus		O
or		O
cowpox		O
virus		O
.		O
Other		O
compounds		O
in		O
this		O
series		O
showed		O
moderate		O
activities		O
(		O
IC50		O
&		O
gt		O
;		O
100		O
nM		O
)		O
on		O
the		O
type		O
II		O
enzyme		O
.		O
These		O
findings		O
are		O
consistent		O
with		O
the		O
hypothesis		O
that		O
the		O
diol		O
epoxide		O
metabolites		O
of		O
these		O
dihydrodiols		O
are		O
the		O
active		O
carcinogenic		O
forms		O
of		O
the		O
parent		O
hydrocarbons		O
.		O
In		O
mouse		O
permanent		O
middle		O
cerebral		O
artery		O
occlusion		O
focal		O
ischemia		O
,		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzothiazolyl		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
adenosine		I-IUPAC
(		O
NNC		O
21-0136		O
,		O
12		O
)		O
exhibited		O
significant		O
neuroprotection		O
at		O
the		O
remarkably		O
low		O
total		O
intraperitoneal		O
dose		O
of		O
0.1		O
mg		O
/		O
kg		O
,		O
a		O
dose		O
at		O
which		O
no		O
cardiovascular		O
effects		O
are		O
observed		O
in		O
conscious		O
rats		O
.		O
For		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
diazidopropyl		I-IUPAC
]		I-IUPAC
adenine		I-IUPAC
and		O
some		O
di		B-MODIFIER
-		I-MODIFIER
and		O
trihydroxybutyl		B-MODIFIER
analogues		I-MODIFIER
of		O
DHPA		O
,		O
viz		O
.		O
Compound		O
21		O
also		O
effectively		O
suppresses		O
seizures		O
induced		O
in		O
Swiss		O
mice		O
by		O
maximal		O
electroshock		O
(		O
MES		O
)		O
and		O
pentylenetetrazole		O
(		O
PTZ		O
)		O
.		O
The		O
irreversible		O
inactivation		O
of		O
the		O
hormone		O
-		O
binding		O
site		O
by		O
the		O
four		O
haloacetamides		O
was		O
prevented		O
by		O
treatment		O
of		O
the		O
cytosol		O
with		O
the		O
thiol		O
-		O
specific		O
reagent		O
methyl		O
methanethiosulfonate		O
,		O
suggesting		O
that		O
the		O
target		O
of		O
these		O
compounds		O
was		O
probably		O
the		O
-		O
SH		O
of		O
cysteines		O
.		O
Also		O
,		O
4c		O
,		O
d		O
were		O
evaluated		O
for		O
their		O
ability		O
to		O
compete		O
against		O
agonist		O
and		O
antagonist		O
radioligands		O
at		O
cloned		O
human		O
5		O
-		O
HT2A		O
,		O
5		O
-		O
HT2B		O
,		O
and		O
5		O
-		O
HT2C		O
receptors		O
.		O
Against		O
P		O
.		O
Alkoxymethyl		O
,		O
acyloxymethyl		O
,		O
and		O
mixed		O
alkylalkoxymethyl		O
or		O
alkylacyloxymethyl		O
derivatives		O
of		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenylhydantoin		I-IUPAC
exhibit		O
anticonvulsant		O
activity		O
.		O
The		O
central		O
metal		O
ions		O
exert		O
pronounced		O
effects		O
in		O
a		O
divergent		O
manner		O
:		O
gallium		O
(		O
III		O
)		O
enhances		O
,		O
whereas		O
iron		O
(		O
III		O
)		O
weakens		O
the		O
cytotoxicity		O
of		O
the		O
ligands		O
.		O
In		O
summary		O
,		O
the		O
4,4		B-IUPAC
-		I-IUPAC
triamine		I-IUPAC
motif		B-MODIFIER
was		O
shown		O
to		O
facilitate		O
entry		O
of		O
polyamine		O
conjugates		O
into		O
cells		O
containing		O
active		O
polyamine		O
transporters		O
.		O
Lipophilic		O
methotrexate		O
(		O
MTX		O
)		O
and		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
dichloromethotrexate		I-IUPAC
(		O
DCM		O
)		O
diesters		B-MODIFIER
were		O
prepared		O
by		O
HCl		O
-		O
catalyzed		O
esterification		O
or		O
by		O
neutral		O
esterification		O
using		O
cesium		O
carbonate		O
and		O
an		O
alkyl		O
or		O
aralkyl		O
halide		O
in		O
Me2SO		O
.		O
A		O
cellular		O
debenzylation		O
process		O
was		O
observed		O
in		O
L1210		O
cells		O
with		O
6		O
and		O
generated		O
"		O
free		O
"		O
homospermidine		O
.		O
For		O
ligands		O
with		O
a		O
log		O
Dligand		O
=		O
-		O
1		O
,		O
a		O
linear		O
relationship		O
exists		O
with		O
a		O
value		O
of		O
the		O
slope		O
2.53		O
,		O
whereas		O
with		O
ligands		O
with		O
a		O
log		O
Dligand		O
&		O
lt		O
;		O
-		O
1		O
,		O
a		O
linear		O
relationship		O
exists		O
with		O
a		O
slope		O
of		O
0.49		O
.		O
,		O
by		O
the		O
action		O
of		O
converting		O
enzyme		O
on		O
the		O
nonapeptide		O
IV		O
,		O
and		O
(		O
b		O
)		O
that		O
III		O
may		O
also		O
be		O
acting		O
as		O
inhibitor		O
of		O
the		O
converting		O
enzyme		O
by		O
the		O
feedback		O
mechanism		O
.		O
In		O
a		O
structure		O
-		O
activity		O
comparison		O
it		O
was		O
found		O
that		O
the		O
oxygen		O
atom		O
in		O
the		O
2		B-MODIFIER
-		I-MODIFIER
(		I-MODIFIER
substituted		I-MODIFIER
-		I-MODIFIER
oxy		I-MODIFIER
)		I-MODIFIER
ethyl		I-MODIFIER
group		B-MODIFIER
at		O
the		O
1		O
-		O
position		O
of		O
the		O
benzimidazole		O
nucleus		O
played		O
an		O
important		O
role		O
for		O
potent		O
antihistaminic		O
activity		O
,		O
especially		O
in		O
vivo		O
.		O
f		O
.		O
/		O
100		O
mL		O
of		O
tissue		O
)		O
.		O
In		O
rat		O
experiments		O
,		O
the		O
(		O
18		O
)		O
F		O
-		O
labeled		O
candidate		O
showed		O
desirable		O
properties		O
for		O
PET		O
AChE		O
measurement		O
:		O
high		O
brain		O
uptake		O
of		O
the		O
authentic		O
ester		O
,		O
high		O
AChE		O
specificity		O
,		O
a		O
moderate		O
hydrolysis		O
rate		O
,		O
and		O
low		O
membrane		O
permeability		O
(		O
metabolic		O
trapping		O
)		O
of		O
the		O
metabolite		O
.		O
The		O
synthesis		O
and		O
in		O
vitro		O
sigma		O
receptor		O
activity		O
of		O
the		O
two		O
diastereomers		O
of		O
U50		O
,		O
488		O
[		O
(		O
+		O
/		O
-		O
)		O
-		O
2		O
]		O
,		O
namely		O
,		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
benzeneacet		I-IUPAC
ami		I-IUPAC
de		I-IUPAC
[		B-PARTIUPAC
(		I-PARTIUPAC
+		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
1		I-PARTIUPAC
]		I-PARTIUPAC
and		O
(		B-IUPAC
1S		I-IUPAC
,		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
benzeneacetamide		I-IUPAC
[		O
(		O
-		O
)		O
-		O
1		O
]		O
,		O
are		O
described		O
.		O
The		O
structure		O
-		O
activity		O
findings		O
led		O
to		O
a		O
refinement		O
of		O
a		O
model		O
of		O
the		O
nonprostanoid		O
PGI2		O
mimetic		O
pharmacophore		O
.		O
The		O
crystal		O
structure		O
and		O
final		O
molecular		O
structure		O
of		O
one		O
of		O
these		O
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyhexahydroazepin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
tolylsulfonylurea		I-IUPAC
(		O
5		O
)		O
,		O
were		O
determined		O
using		O
single		O
-		O
crystal		O
X		O
-		O
ray		O
techniques		O
.		O
At		O
physiological		O
pH		O
,		O
the		O
spatial		O
arrangement		O
of		O
the		O
three		O
charges		O
of		O
DL		B-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylglycine		I-IUPAC
(		O
5		O
)		O
could		O
be		O
viewed		O
as		O
similar		O
to		O
those		O
found		O
in		O
certain		O
conformations		O
of		O
the		O
two		O
excitatory		O
amino		O
acids		O
(		O
EAAs		O
)		O
-		O
-		O
aspartic		O
and		O
glutamic		O
acids		O
.		O
In		O
order		O
to		O
study		O
the		O
toxicities		O
of		O
4		O
and		O
5		O
released		O
under		O
drug		O
metabolizing		O
conditions		O
independently		O
of		O
the		O
production		O
of		O
a		O
toxic		O
mustard		O
the		O
analogs		B-MODIFIER
18		O
[		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diethylamino		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1,3,2		I-IUPAC
-		I-IUPAC
oxazaphosphorine		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
]		O
and		O
6		O
[		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diethylamino		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
trifluoromethyl		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1,3,2		I-IUPAC
-		I-IUPAC
oxazaphosphorine		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
]		O
were		O
also		O
synthesized		O
.		O
Primary		O
and		O
secondary		O
amines		O
bound		O
with		O
lower		O
affinity		O
than		O
tertiary		O
amines		O
.		O
Conformational		O
studies		O
(		O
NMR		O
,		O
X		O
-		O
ray		O
crystallography		O
)		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
pyrazinylcarboxamidobenzoates		I-IUPAC
indicate		O
that		O
the		O
preferred		O
conformation		O
exhibits		O
a		O
trans		O
-		O
amide		O
bond		O
and		O
an		O
internal		O
hydrogen		O
bond		O
between		O
the		O
quinoxaline		O
N1		O
and		O
HN		O
amide		O
which		O
locks		O
the		O
torsional		O
angle		O
between		O
C2		O
and		O
CO		O
in		O
the		O
s		O
-		O
trans		O
conformation		O
.		O
Kinetic		O
comparison		O
of		O
the		O
iodomethylene		O
lactone		O
3		O
with		O
the		O
corresponding		O
protio		O
lactone		O
25		O
indicates		O
that		O
the		O
iodine		O
accelerates		O
the		O
rate		O
of		O
chymotrypsin		O
acylation		O
but		O
produces		O
an		O
acyl		O
enzyme		O
that		O
is		O
more		O
hydrolytically		O
labile		O
than		O
that		O
formed		O
from		O
lactone		O
25		O
.		O
Also		O
,		O
both		O
folic		O
acid		O
and		O
5		O
-		O
(		O
CHO		O
)		O
-		O
THF		O
were		O
reductively		O
alkylated		O
with		O
formaldehyde		O
to		O
give		O
10		B-IUPAC
-		I-IUPAC
methylfolic		I-IUPAC
acid		I-IUPAC
(		O
6		O
)		O
and		O
5		O
-		O
(		O
CHO		O
)		O
-		O
10		O
-		O
(		O
CH3		O
)		O
-		O
THF		O
(		O
28		O
)		O
,		O
respectively		O
.		O
The		O
structural		O
assignments		O
for		O
6f		O
and		O
6g		O
are		O
made		O
on		O
the		O
basis		O
of		O
1H		O
and		O
13C		O
NMR		O
spectral		O
analyses		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
methylthio		I-IUPAC
)		I-IUPAC
nicotinates		I-IUPAC
(		O
7f		O
,		O
g		O
)		O
prepared		O
from		O
6f		O
and		O
6g		O
by		O
treatment		O
with		O
MeI		O
/		O
K2CO3		O
.		O
Oral		O
administration		O
of		O
CV		O
-		O
11974		O
to		O
conscious		O
normotensive		O
rats		O
at		O
1		O
mg		O
/		O
kg		O
resulted		O
in		O
long		O
-		O
lasting		O
inhibition		O
of		O
the		O
AII		O
-		O
induced		O
pressor		O
response		O
.		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
Quinolyl		I-IUPAC
)		I-IUPAC
glycine		I-IUPAC
hydrazide		I-IUPAC
(		O
18		O
)		O
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
quinolylamino		I-IUPAC
)		I-IUPAC
butyric		I-IUPAC
acid		I-IUPAC
hydrazide		I-IUPAC
(		O
24		O
)		O
,		O
which		O
are		O
bioisosteres		O
of		O
compounds		O
1		O
and		O
23		O
,		O
showed		O
loss		O
of		O
antitubercular		O
activity		O
at		O
low		O
concentrations		O
.		O
The		O
rank		O
order		O
of		O
potency		O
of		O
agonists		O
was		O
[		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
approximately		O
[		O
p		O
-		O
F		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
&		O
gt		O
;		O
[		O
p		O
-		O
NH		O
(		O
2		O
)		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
&		O
gt		O
;		O
[		O
p		O
-		O
Cl		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
&		O
gt		O
;		O
[		O
p		O
-		O
NO		O
(		O
2		O
)		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
&		O
gt		O
;		O
[		O
Trp		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
.		O
Analogues		O
22		O
and		O
23		O
were		O
also		O
more		O
potent		O
than		O
astressin		O
at		O
reversing		O
intracisternal		O
CRF		O
-		O
and		O
abdominal		O
surgery		O
-		O
induced		O
delay		O
of		O
gastric		O
emptying		O
in		O
conscious		O
rats		O
.		O
3D		O
QSAR		O
models		O
were		O
derived		O
for		O
2		B-IUPAC
-		I-IUPAC
pyridinylguanidines		I-IUPAC
(		O
training		O
set		O
N		O
=		O
25		O
,		O
test		O
set		O
N		O
=		O
8		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
aminoarylguanidines		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
aminoarylbenzamidines		I-IUPAC
(		O
training		O
set		O
N		O
=		O
29		O
,		O
test		O
set		O
N		O
=		O
8		O
)		O
,		O
thiophene		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxamindines		I-IUPAC
(		O
training		O
set		O
N		O
=		O
64		O
,		O
test		O
set		O
N		O
=		O
19		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
naphthamidines		I-IUPAC
(		O
training		O
set		O
N		O
=		O
32		O
,		O
test		O
set		O
N		O
=		O
8		O
)		O
,		O
and		O
1		B-IUPAC
-		I-IUPAC
isoquinolinylguanidines		I-IUPAC
(		O
training		O
set		O
N		O
=		O
29		O
,		O
test		O
set		O
N		O
=		O
7		O
)		O
.		O
However		O
,		O
like		O
4c		O
,		O
e		O
,		O
4d		O
did		O
not		O
significantly		O
affect		O
the		O
binding		O
of		O
the		O
competitive		O
NMDA		O
antagonist		O
,		O
[		O
3H		O
]		O
CPP		O
,		O
or		O
the		O
noncompetitive		O
NMDA		O
antagonist		O
,		O
[		O
3H		O
]		O
MK		O
-		O
801		O
.		O
The		O
phenolic		O
compound		O
7		O
,		O
however		O
,		O
could		O
be		O
phosphorylated		O
only		O
by		O
using		O
the		O
phosphoramidite		O
method		O
.		O
Calpain		O
I		O
was		O
also		O
effectively		O
inhibited		O
,		O
but		O
very		O
low		O
Ki		O
values		O
were		O
observed		O
with		O
a		O
smaller		O
number		O
of		O
inhibitors		O
than		O
with		O
calpain		O
II		O
.		O
Cytosine		O
,		O
adenine		O
,		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
,		O
thymine		O
,		O
and		O
(		B-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butene		I-IUPAC
gave		O
compounds		O
4c		O
-		O
f		O
,		O
which		O
,		O
after		O
hydrolysis		O
,		O
afforded		O
alcohols		O
4a		O
,		O
4b		O
,		O
4g		O
,		O
and		O
4h		O
.		O
The		O
5		B-PARTIUPAC
-		I-PARTIUPAC
halo		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
alkoxy		I-PARTIUPAC
(		O
or		O
azido		B-PARTIUPAC
)		O
-		B-PARTIUPAC
5,6		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
azido		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
deoxythymidines		I-PARTIUPAC
,		O
which		O
differ		O
in		O
configuration		O
at		O
the		O
C		O
-		O
5		O
and		O
C		O
-		O
6		O
positions		O
,		O
were		O
synthesized		O
by		O
the		O
regiospecific		O
addition		O
of		O
XR		O
(		O
X		O
=		O
Br		O
,		O
Cl		O
,		O
I		O
;		O
R		O
=		O
alkoxy		O
,		O
azido		O
)		O
to		O
the		O
5,6		O
-		O
olefinic		O
bond		O
of		O
AZT		O
.		O
Compounds		O
18		O
and		O
23b		O
were		O
active		O
at		O
concentrations		O
very		O
similar		O
to		O
pyrazofurin		O
but		O
are		O
less		O
toxic		O
to		O
the		O
cells		O
than		O
pyrazofurin		O
.		O
The		O
binding		O
affinities		O
of		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
c		O
[		O
H		O
-		O
Cys		O
-		O
Lys		O
-		O
Phe		O
-		O
Phe		O
-		O
DTrp		O
-		O
IAmp		O
-		O
Thr		O
-		O
Phe		O
-		O
Thr		O
-		O
Ser		O
-		O
Cys		O
-		O
OH		O
]		O
,		O
CH		O
-		O
275		O
)		O
(		O
7		O
)		O
,		O
des		O
-		O
AA		O
(		O
1,5		O
)		O
-		O
[		O
Tyr		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
CH		O
-		O
288		O
)		O
(		O
16		O
)		O
,		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
Tyr		O
(		O
7		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
23		O
)		O
,		O
and		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
,		O
Tyr		O
(		O
11		O
)		O
]		O
-		O
SRIF		O
(		O
25		O
)		O
are		O
about		O
(		O
1		O
)		O
/		O
(		O
7		O
)		O
,		O
(		O
1		O
)		O
/		O
(		O
4		O
)		O
,		O
(		O
1		O
)		O
/		O
(		O
125		O
)		O
,		O
and		O
(		O
1		O
)		O
/		O
(		O
4		O
)		O
that		O
of		O
SRIF		O
-		O
28		O
(		O
1		O
)		O
to		O
sst1		O
,		O
respectively		O
,		O
about		O
(		O
1		O
)		O
/		O
(		O
65		O
)		O
,		O
(		O
1		O
)		O
/		O
(		O
130		O
)		O
,		O
&		O
lt		O
;		O
(		O
1		O
)		O
/		O
(		O
1000		O
)		O
,		O
and		O
&		O
lt		O
;		O
(		O
1		O
)		O
/		O
(		O
150		O
)		O
that		O
of		O
1		O
to		O
sst3		O
,		O
respectively		O
,		O
and		O
about		O
or		O
less		O
than		O
(		O
1		O
)		O
/		O
(		O
1000		O
)		O
that		O
of		O
1		O
to		O
the		O
other		O
three		O
human		O
SRIF		O
receptor		O
subtypes		O
.		O
avium		O
DHFR		O
,		O
and		O
55		O
nM		O
against		O
rat		O
DHFR		O
.		O
The		O
ability		O
to		O
inhibit		O
reuptake		O
of		O
dopamine		O
in		O
comparison		O
to		O
cocaine		O
is		O
generally		O
decreased		O
in		O
this		O
series		O
but		O
for		O
one		O
compound		O
.		O
The		O
amines		O
(		O
+		O
)		O
-		O
and		O
(		O
-		O
)		O
-		O
14a		O
,		O
incorporating		O
the		O
D1		O
pharmacophore		O
2		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
ethylamine		I-IUPAC
in		O
a		O
trans		O
extended		O
conformation		O
,		O
and		O
their		O
derivatives		O
displayed		O
D1		O
and		O
D2		O
affinity		O
in		O
the		O
nanomolar		O
range		O
.		O
The		O
results		O
suggest		O
the		O
existence		O
of		O
a		O
biphasic		O
relationship		O
between		O
the		O
distribution		O
coefficient		O
values		O
of		O
the		O
chelator		O
and		O
the		O
corresponding		O
iron		O
(		O
III		O
)		O
complexes		O
.		O
N		O
-		O
Oxidation		O
of		O
1,5		B-IUPAC
-		I-IUPAC
dimethylisoquinoline		I-IUPAC
,		O
followed		O
by		O
rearrangement		O
with		O
acetic		O
anhydride		O
,		O
gave		O
,		O
after		O
acid		O
hydrolysis		O
,		O
1,5		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyisoquinoline		I-IUPAC
,		O
which		O
was		O
converted		O
to		O
its		O
acetate		O
and		O
then		O
oxidized		O
to		O
yield		O
4		B-IUPAC
-		I-IUPAC
acetoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoquinoline		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
carboxaldehyde		I-IUPAC
(		O
32		O
)		O
.		O
Conversely		O
,		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorobenzylamino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
cyclopropane		I-IUPAC
(		O
10a		O
)		O
with		O
the		O
(		O
1R		O
)		O
-		O
trans		O
structure		O
was		O
selective		O
for		O
the		O
H4		O
receptor		O
(		O
Ki		O
=		O
118		O
nM		O
)		O
compared		O
to		O
the		O
H3		O
receptor		O
(		O
Ki		O
&		O
gt		O
;		O
10		O
(		O
3		O
)		O
nM		O
)		O
.		O
To		O
substantiate		O
that		O
the		O
(		B-IUPAC
131		I-IUPAC
)		I-IUPAC
I		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hetero		I-IUPAC
)		I-IUPAC
arylmethylene		I-IUPAC
group		B-MODIFIER
at		O
the		O
O		O
(		O
6		O
)		O
-		O
position		O
of		O
guanine		O
is		O
transferred		O
to		O
MGMT		O
,		O
both		O
the		O
glucose		O
conjugated		O
inhibitors		O
ITGG		O
and		O
IBGG		O
and		O
the		O
corresponding		O
nonglucose		O
conjugated		O
compounds		O
ITG		O
and		O
IBG		O
were		O
labeled		O
with		O
iodine		O
-		O
131		O
.		O
The		O
N		O
-		O
N		O
-		O
N		O
spacings		O
appear		O
to		O
be		O
an		O
important		O
factor		O
in		O
their		O
sigma		O
-		O
2		O
subtype		O
selectivity		O
.		O
This		O
and		O
the		O
subsequent		O
publication		O
look		O
at		O
the		O
AMPA		O
antagonist		O
aspects		O
of		O
this		O
SAR		O
.		O
In		O
a		O
displacement		O
experiment		O
of		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
in		O
a		O
cynomolgus		O
monkey		O
,		O
radioactivity		O
was		O
reduced		O
by		O
39%		O
in		O
the		O
diencephalon		O
at		O
101		O
min		O
following		O
injection		O
of		O
citalopram		O
.		O
Compound		O
4a		O
was		O
prepared		O
via		O
selective		O
bromination		O
of		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
nicotinonitrile		I-IUPAC
(		O
2a		O
)		O
with		O
N		B-IUPAC
-		I-IUPAC
bromosuccinimide		I-IUPAC
,		O
followed		O
by		O
Suzuki		O
coupling		O
with		O
4		B-IUPAC
-		I-IUPAC
cyanophenylboronic		I-IUPAC
acid		I-IUPAC
.		O
Moderate		O
activity		O
was		O
observed		O
with		O
2a		O
and		O
2b		O
while		O
1d		O
and		O
2c		O
were		O
essentially		O
inactive		O
.		O
Several		O
of		O
the		O
new		O
indoles		O
showed		O
selectivity		O
for		O
the		O
alpha		O
(		O
1		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2		O
)		O
subtype		O
compared		O
with		O
the		O
alpha		O
(		O
3		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2		O
)		O
and		O
alpha		O
(		O
5		O
)		O
beta		O
(		O
3		O
)		O
gamma		O
(		O
2		O
)		O
subtypes		O
(		O
e.g.		O
:		O
4t		O
and		O
7c		O
bind		O
to		O
these		O
three		O
BzR		O
isoforms		O
with		O
K		O
(		O
i		O
)		O
values		O
of		O
14		O
nM		O
,		O
283		O
nM		O
,		O
239		O
nM		O
,		O
and		O
9		O
nM		O
,		O
1960		O
nM		O
,		O
95		O
nM		O
,		O
respectively		O
)		O
.		O
With		O
a		O
thiochroman		O
unit		O
,		O
the		O
most		O
active		O
acids		O
in		O
decreasing		O
order		O
of		O
activity		O
in		O
the		O
ODC		O
assay		O
were		O
7		O
greater		O
than		O
9		O
greater		O
than		O
8		O
.		O
ethanolamine		I-IUPAC
complex		B-MODIFIER
(		O
8		O
)		O
,		O
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
adamantane		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenylpropionic		I-IUPAC
acid		I-IUPAC
(		O
15		O
)		O
show		O
a		O
dose		O
-		O
dependent		O
,		O
astrocyte		O
-		O
selective		O
antiproliferative		O
activity		O
in		O
the		O
concentration		O
range		O
0.1-10		O
microM		O
.		O
Two		O
alkylating		O
glucocorticoids		O
have		O
been		O
synthesized		O
in		O
order		O
to		O
test		O
the		O
possibility		O
of		O
alkylating		O
glucocorticoid		O
receptors		O
.		O
Comparison		O
of		O
the		O
HPLC		O
retention		O
times		O
,		O
diode		O
array		O
UV		O
,		O
and		O
chemical		O
ion		O
mass		O
spectral		O
characteristics		O
of		O
these		O
products		O
with		O
those		O
of		O
synthetic		O
standards		O
led		O
us		O
to		O
propose		O
the		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydropyridinium		I-IUPAC
species		O
2,3		O
-		O
MPDP+		O
and		O
6		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
as		O
tentative		O
structure		O
assignments		O
for		O
the		O
dihydropyridinium		O
metabolite		O
and		O
the		O
cyano		O
adduct		O
,		O
respectively		O
.		O
Glycosylation		O
of		O
persilylated		O
as		O
well		O
as		O
nonsilylated		O
3		B-IUPAC
-		I-IUPAC
bromoallopurinol		I-IUPAC
with		O
1		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranose		I-IUPAC
(		O
4		O
)		O
provided		O
the		O
key		O
intermediate		O
3		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
5H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
5a		O
)		O
.		O
All		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		O
substituted		B-MODIFIER
-		O
5,6		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
compounds		B-MODIFIER
were		O
inactive		O
,		O
except		O
for		O
the		O
approximately		O
equipotent		O
6		O
-		O
OMe		O
and		O
6		B-IUPAC
-		I-IUPAC
azido		I-IUPAC
diastereomeric		I-IUPAC
mixtures		B-MODIFIER
which		O
were		O
2-3		O
log		O
units		O
less		O
active		O
than		O
the		O
reference		O
drug		O
AZT		O
.		O
for		O
the		O
PAF		O
-		O
induced		O
mortality		O
test		O
in		O
mice		O
)		O
.		O
A		O
series		O
of		O
aza		B-IUPAC
-		I-IUPAC
5		I-IUPAC
[		I-IUPAC
H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
phenanthridin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
were		O
synthesized		O
and		O
evaluated		O
as		O
inhibitors		O
of		O
poly		O
ADP		O
-		O
ribose		O
polymerase		O
-		O
1		O
(		O
PARP		O
-		O
1		O
)		O
.		O
Significant		O
antitetrabenazine		O
activity		O
is		O
associated		O
only		O
with		O
derivatives		O
where		O
the		O
arylmethyl		O
group		O
is		O
ortho		O
to		O
the		O
piperidine		O
ring		O
.		O
Application		O
of		O
lactam		O
constraints		O
in		O
the		O
C		O
-		O
terminus		O
of		O
GHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
identified		O
cyclo		O
(		O
25-29		O
)		O
[		O
MeTyr1		O
,		O
Ala15		O
,		O
DAsp25		O
,		O
Nle27		O
,		O
Orn29+		O
+		O
+		O
]		O
-		O
hGHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
(		O
46		O
)		O
as		O
containing		O
the		O
optimum		O
bridging		O
element		O
(		O
19		O
-		O
membered		O
ring		O
)		O
in		O
this		O
region		O
of		O
the		O
molecule		O
.		O
1		B-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
Naphthyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
analogues		B-MODIFIER
bearing		O
basic		O
aliphatic		O
side		O
chains		O
[		O
7		O
-		O
NH		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
n		O
)		O
(		O
)		O
NRR		O
,		O
7		O
-		O
NHPhO		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
n		O
)		O
(		O
)		O
NRR		O
,		O
or		O
7		O
-		O
NHPhN		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
4		O
)		O
NMe		O
]		O
were		O
the		O
most		O
potent		O
against		O
c		O
-		O
Src		O
(		O
IC		O
(		O
50		O
)		O
s		O
of		O
10-80		O
nM		O
)		O
,		O
showing		O
good		O
selectivity		O
with		O
respect		O
to		O
PDGFR		O
(		O
10-300		O
-		O
fold		O
)		O
but		O
less		O
with		O
respect		O
to		O
FGFR		O
.		O
By		O
means		O
of		O
the		O
pharmacological		O
results		O
obtained		O
on		O
pancreatic		O
B		O
-		O
cells		O
,		O
structure		O
-		O
-		O
activity		O
relationships		O
were		O
deduced		O
and		O
a		O
pharmacophoric		O
model		O
for		O
the		O
interaction		O
of		O
these		O
drugs		O
with		O
their		O
receptor		O
site		O
associated		O
to		O
the		O
pancreatic		O
K		O
(		O
ATP		O
)		O
channel		O
was		O
proposed		O
.		O
In		O
functional		O
in		O
vitro		O
studies		O
on		O
histamine		O
H2		O
,		O
H3		O
,		O
and		O
other		O
neurotransmitter		O
receptors		O
the		O
selectivity		O
of		O
39		O
was		O
found		O
to		O
be		O
2138		O
(		O
H1		O
:		O
H2		O
)		O
,		O
&		O
gt		O
;		O
64		O
(		O
H1		O
:		O
H3		O
)		O
,		O
1000		O
(		O
H1		O
:		O
M3		O
)		O
,		O
105		O
(		O
H1		O
:		O
alpha		O
1		O
)		O
,		O
708		O
(		O
H1		O
:		O
beta		O
1		O
)		O
,		O
and		O
71		O
(		O
H1		O
:		O
5HT2A		O
)		O
.		O
The		O
suppressive		O
effect		O
of		O
5l		O
was		O
the		O
same		O
as		O
that		O
of		O
trimethoprim		O
(		O
10		O
microgram		O
/		O
mL		O
)		O
+		O
sulfamethoxazole		O
(		O
250		O
microgram		O
/		O
mL		O
)		O
,		O
a		O
standard		O
clinical		O
combination		O
for		O
the		O
treatment		O
of		O
P		O
.		O
Dog		O
adrenal		O
medullae		O
were		O
used		O
as		O
a		O
model		O
to		O
test		O
radiotracer		O
affinity		O
for		O
catecholamine		O
storage		O
tissue		O
.		O
These		O
compounds		O
are		O
structurally		O
related		O
to		O
the		O
pyrido		B-PARTIUPAC
[		I-PARTIUPAC
3,2		I-PARTIUPAC
-		I-PARTIUPAC
d		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
and		O
pyrido		B-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
-		I-IUPAC
pyrimidines		I-IUPAC
previously		O
shown		O
to		O
be		O
EGFR		O
inhibitors		O
.		O
Hypoxic		O
cells		O
of		O
solid		O
tumors		O
are		O
an		O
obstacle		O
to		O
effective		O
cancer		O
therapy		O
.		O
This		O
synthesis		O
strategy		O
led		O
to		O
4		O
out		O
of		O
16		O
possible		O
stereoisomers		O
,		O
which		O
were		O
isolated		O
in		O
the		O
case		O
of		O
(		O
-		O
)		O
-		O
3		O
,		O
(		O
+		O
)		O
-		O
3		O
,		O
(		O
-		O
)		O
-		O
4		O
,		O
and		O
(		O
+		O
)		O
-		O
4		O
and		O
whose		O
absolute		O
configuration		O
was		O
assigned		O
using		O
a		O
chiral		O
building		O
block		O
for		O
the		O
synthesis		O
of		O
(		O
-		O
)		O
-		O
3		O
starting		O
from		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
benzodioxine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
(		O
+		O
)		O
-		O
9		O
)		O
and		O
(		B-IUPAC
1S		I-IUPAC
,		I-IUPAC
2S		I-IUPAC
,		I-IUPAC
5S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenoxycyclopentan		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
(		O
+		O
)		O
-		O
10		O
)		O
.		O
When		O
assayed		O
in		O
vivo		O
in		O
the		O
treated		O
rats		O
,		O
the		O
above		O
mentioned		O
isoornithines		O
were		O
also		O
found		O
to		O
inhibit		O
liver		O
ODC		O
when		O
administered		O
1		O
h		O
before		O
sacrifice		O
.		O
The		O
compounds		O
were		O
inactive		O
as		O
antimalarials		O
.		O
Compound		O
9		O
also		O
showed		O
anticonvulsant		O
activity		O
when		O
administered		O
intracerebroventricularly		O
(		O
ED		O
(		O
50		O
)		O
=		O
59		O
nmol		O
)		O
.		O
On		O
incubation		O
with		O
rat		O
plasma		O
,		O
1c		O
liberated		O
nitroxyl		B-IUPAC
,		O
a		O
potent		O
inhibitor		O
of		O
AlDH		O
.		O
Competition		O
binding		O
experiments		O
clearly		O
indicated		O
that		O
the		O
new		O
ligand		O
displayed		O
the		O
expected		O
5		O
-		O
HT1A		O
receptor		O
binding		O
profile		O
.		O
Unlike		O
the		O
case		O
for		O
theophylline		O
,		O
the		O
presence		O
of		O
a		O
phenyl		O
substituent		O
in		O
the		O
five		O
-		O
membered		O
ring		O
did		O
not		O
enhance		O
the		O
potency		O
of		O
a		O
mesoionic		O
thiadiazolopyrimidine		O
.		O
The		O
rest		O
of		O
the		O
hydroxy		O
derivatives		O
,		O
with		O
the		O
exception		O
of		O
4a		O
,		O
were		O
moderately		O
effective		O
or		O
inactive		O
as		O
antiviral		O
agents		O
.		O
Furthermore		O
,		O
the		O
functional		O
activity		O
of		O
(		O
-		O
)		O
-		O
3		O
,		O
(		O
+		O
)		O
-		O
3		O
,		O
(		O
-		O
)		O
-		O
4		O
,		O
and		O
(		O
+		O
)		O
-		O
4		O
toward		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
was		O
evaluated		O
by		O
determining		O
the		O
induced		O
stimulation		O
of		O
[		O
(		O
35		O
)		O
S		O
]		O
GTPgammaS		O
binding		O
in		O
cell		O
membranes		O
from		O
HeLa		O
cells		O
transfected		O
with		O
human		O
cloned		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
.		O
Reduction		O
of		O
6		O
to		O
7		O
and		O
treatment		O
with		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
trichloroethoxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzylhydroxylamine		I-IUPAC
(		O
8		O
)		O
,		O
and		O
diethyl		B-IUPAC
azodicarboxylate		I-IUPAC
and		O
triphenylphosphine		O
followed		O
by		O
deprotection		O
produced		O
the		O
protected		O
N5		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
N5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
derivatives		B-MODIFIER
11		O
and		O
12		O
in		O
large		O
quantities		O
(		O
10-20		O
g		O
)		O
.		O
In		O
general		O
,		O
distal		O
modifications		O
of		O
the		O
N5		O
-		O
substituent		O
were		O
highly		O
modulatory		O
to		O
potency		O
and		O
selectivity		O
at		O
adenosine		O
receptors		O
,		O
as		O
determined		O
in		O
radioligand		O
binding		O
assays		O
at		O
rat		O
brain		O
A1		O
and		O
A2A		O
receptors		O
and		O
at		O
recombinant		O
human		O
A3		O
receptors		O
.		O
(		B-IUPAC
3S		I-IUPAC
,		I-IUPAC
4aR		I-IUPAC
,		I-IUPAC
6R		I-IUPAC
,		I-IUPAC
8aR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4,4		I-IUPAC
a		I-IUPAC
,		I-IUPAC
5,6,7,8,8		I-IUPAC
a		I-IUPAC
-		I-IUPAC
decahydroisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
9		O
)		O
is		O
a		O
potent		O
,		O
selective		O
and		O
systemically		O
active		O
AMPA		O
antagonist		O
.		O
In		O
this		O
report		O
,		O
we		O
describe		O
structure		O
-		O
activity		O
studies		O
of		O
the		O
bicyclic		O
oxytocin		O
antagonist		O
[		O
Mpa1		O
,		O
cyclo		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
.		O
Consistent		O
with		O
earlier		O
results		O
with		O
polyamine		O
analogues		O
,		O
these		O
studies		O
underscore		O
the		O
importance		O
of		O
charge		O
in		O
the		O
design		O
of		O
polyamine		O
-		O
vectored		O
chelators		O
.		O
This		O
compound		O
is		O
a		O
potent		O
(		O
K		O
(		O
i		O
)		O
=		O
1.6		O
nM		O
)		O
and		O
selective		O
inhibitor		O
of		O
serotonin		O
reuptake		O
into		O
rat		O
midbrain		O
synaptosomes		O
.		O
This		O
approach		O
found		O
an		O
isosteric		O
amide		O
structure		O
,		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethyl		I-IUPAC
)		I-IUPAC
amide		I-IUPAC
,		O
suitable		O
in		O
terms		O
of		O
potency		O
and		O
stability		O
.		O
These		O
furanyl		B-IUPAC
and		O
pyranyl		B-IUPAC
derivatives		B-MODIFIER
were		O
tested		O
for		O
antileukemic		O
activity		O
(		O
L		O
-		O
1210		O
,		O
in		O
vivo		O
)		O
and		O
the		O
results		O
were		O
compared		O
with		O
the		O
results		O
obtained		O
for		O
the		O
corresponding		O
ribosyl		B-IUPAC
derivatives		B-MODIFIER
of		O
DTIC		O
and		O
DTPC		O
.		O
These		O
data		O
indicate		O
that		O
such		O
compounds		O
penetrate		O
the		O
blood		O
-		O
brain		O
barrier		O
but		O
their		O
MES		O
activity		O
may		O
not		O
be		O
related		O
to		O
NMDA		O
receptor		O
antagonism		O
.		O
Three		O
N		B-IUPAC
-		I-IUPAC
fluoroethyl		I-IUPAC
-		I-IUPAC
substituted		B-MODIFIER
(		B-IUPAC
imidazolylphenyl		I-IUPAC
)		I-IUPAC
formamidine		I-IUPAC
derivatives		B-MODIFIER
,		O
namely		O
,		O
2		B-IUPAC
-		I-IUPAC
fluoroethyl		I-IUPAC
(		O
3b		O
)		O
,		O
2,2		B-IUPAC
-		I-IUPAC
difluoroethyl		I-IUPAC
(		O
3c		O
)		O
,		O
and		O
2,2,2		B-IUPAC
-		I-IUPAC
trifluoroethyl		I-IUPAC
(		O
3d		O
)		O
,		O
were		O
prepared		O
to		O
test		O
the		O
effect		O
of		O
fluorine		O
substitution		O
on		O
basicity		O
and		O
,		O
then		O
,		O
on		O
H2		O
-		O
antagonist		O
affinity		O
in		O
comparison		O
with		O
the		O
unsubstituted		B-MODIFIER
N		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
derivative		B-MODIFIER
(		O
3a		O
)		O
,		O
taken		O
as		O
a		O
model		O
of		O
mifentidine		O
.		O
The		O
(		B-IUPAC
N		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methanocarba		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylthio		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
chloromonophosphate		I-IUPAC
analogues		B-MODIFIER
were		O
full		O
agonists		O
exhibiting		O
micromolar		O
potency		O
at		O
P2Y		O
(		O
1		O
)		O
receptors		O
,		O
while		O
the		O
corresponding		O
ribosides		O
were		O
inactive		O
.		O
Compound		O
13		O
,		O
which		O
showed		O
the		O
highest		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptor		O
affinity		O
(		O
K		O
(		O
i		O
)		O
=		O
1.1		O
nM		O
)		O
,		O
was		O
50		O
-		O
fold		O
selective		O
in		O
relation		O
to		O
alpha		O
(		O
1		O
)		O
adrenoceptors		O
and		O
at		O
least		O
250		O
-		O
fold		O
over		O
5		O
-		O
HT		O
(		O
2A		O
)		O
and		O
D		O
(		O
2		O
)		O
sites		O
.		O
The		O
simplest		O
target		O
compounds		O
derived		O
from		O
this		O
template		O
(		O
3e		O
and		O
3f		O
)		O
have		O
one		O
of		O
the		O
hydroxyl		B-IUPAC
moieties		B-MODIFIER
functionalized		O
either		O
as		O
a		O
myristate		O
or		O
as		O
an		O
oleate		O
ester		O
.		O
The		O
in		O
vitro		O
antitumor		O
potency		O
was		O
studied		O
in		O
two		O
human		O
cancer		O
cell		O
lines		O
(		O
41M		O
and		O
SK		O
-		O
BR		O
-		O
3		O
)		O
.		O
The		O
replacement		O
of		O
the		O
X		O
=		O
bridge		O
in		O
1a		O
with		O
the		O
X		O
=		O
N		O
(		O
CH3		O
)		O
group		O
resulted		O
in		O
lowering		O
of		O
the		O
anticancer		O
activity		O
.		O
3		B-IUPAC
-		I-IUPAC
Benzylaminomethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
quinolone		I-IUPAC
(		O
1e		O
)		O
and		O
3,3		B-IUPAC
'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
benzyliminodimethylene		I-IUPAC
)		I-IUPAC
di		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
quinolone		I-IUPAC
]		I-IUPAC
(		O
6b		O
)		O
were		O
also		O
synthesized		O
.		O
The		O
resulting		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
benzamide		I-IUPAC
(		O
23		O
)		O
was		O
about		O
15		O
times		O
more		O
active		O
than		O
metoclopramide		O
.		O
(		B-IUPAC
1S		I-IUPAC
,		I-IUPAC
3R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
thienylmethylene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
azatricyclo		I-IUPAC
[		I-IUPAC
4.3.1.0		I-IUPAC
(		I-IUPAC
3		I-IUPAC
,		I-IUPAC
7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
decane		I-IUPAC
-		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
(		O
5h		O
)		O
exhibits		O
reasonable		O
activity		O
at		O
the		O
dopamine		O
transporter		O
(		O
DAT		O
)		O
(		O
K		O
(		O
i		O
)		O
=		O
268		O
nM		O
)		O
and		O
good		O
activity		O
at		O
the		O
norepinephrine		O
transporter		O
(		O
NET		O
)		O
(		O
K		O
(		O
i		O
)		O
=		O
26		O
nM		O
)		O
.		O
Overexpression		O
of		O
uPA		O
and		O
uPAR		O
in		O
cancer		O
tissues		O
is		O
associated		O
with		O
a		O
high		O
incidence		O
of		O
disease		O
recurrence		O
and		O
early		O
death		O
.		O
Similarly		O
,		O
the		O
two		O
aporphine		O
mustard		O
congeners		O
(		O
1f		O
,		O
g		O
)		O
were		O
also		O
inactive		O
in		O
the		O
P388		O
system		O
.		O
All		O
new		O
compounds		O
are		O
N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
omega		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
1,2,3,4		I-PARTIUPAC
-		I-PARTIUPAC
tetrahydronaphthalen		I-PARTIUPAC
-		I-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
yl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
or		O
-		B-PARTIUPAC
omega		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
1,2		I-PARTIUPAC
-		I-PARTIUPAC
dihydronaphthalen		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
yl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
n		I-PARTIUPAC
-		I-PARTIUPAC
alkylamines		I-PARTIUPAC
with		O
,		O
in		O
some		O
cases		O
,		O
a		O
methoxy		B-IUPAC
group		B-MODIFIER
on		O
the		O
tetralin		O
moiety		O
.		O
A		O
novel		O
series		O
of		O
10		B-IUPAC
-		I-IUPAC
benzylidene		I-IUPAC
-		I-IUPAC
9		I-IUPAC
(		I-IUPAC
10H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
anthracenones		I-IUPAC
and		O
10		B-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
(		I-IUPAC
10H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
anthracenones		I-IUPAC
were		O
synthesized		O
and		O
evaluated		O
for		O
antiproliferative		O
activity		O
in		O
an		O
assay		O
based		O
on		O
K562		O
leukemia		O
cells		O
.		O
These		O
compounds		O
have		O
also		O
been		O
screened		O
against		O
Litomosoides		O
carinii		O
,		O
and		O
of		O
these		O
only		O
3f		O
and		O
5a		O
have		O
also		O
been		O
found		O
to		O
be		O
active		O
.		O
For		O
the		O
enantiomers		O
(		O
+		O
)		O
-		O
4		O
and		O
(		O
-		O
)		O
-		O
4		O
also		O
a		O
remarkable		O
selectivity		O
was		O
achieved		O
.		O
The		O
selectivity		O
level		O
over		O
the		O
adenosine		O
A1		O
receptor		O
subtype		O
for		O
some		O
of		O
the		O
more		O
active		O
analogues		O
is		O
also		O
fairly		O
high		O
,		O
&		O
gt		O
;		O
400		O
-		O
fold		O
in		O
some		O
cases		O
.		O
All		O
three		O
phospholipids		O
were		O
synthesized		O
from		O
the		O
versatile		O
starting		O
material		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
glycidol		I-IUPAC
.		O
Pyrrolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
derivatives		B-MODIFIER
which		O
were		O
simultaneously		O
substituted		O
at		O
N7		O
and		O
N		O
(		O
4		O
)		O
,		O
combining		O
the		O
substitution		O
pattern		O
of		O
ADPEP		O
(		O
1		O
)		O
and		O
DPEAP		O
(		O
2		O
)		O
,		O
showed		O
very		O
low		O
affinity		O
for		O
A		O
(		O
1		O
)		O
ARs		O
.		O
The		O
latter		O
were		O
resolved		O
directly		O
by		O
chromatography		O
.		O
Imidazolylphenyl		O
isothiocyanate		O
(		O
1		O
)		O
,		O
obtained		O
by		O
reaction		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
with		O
carbon		O
disulfide		O
and		O
ethyl		B-IUPAC
chloroformate		I-IUPAC
,		O
was		O
condensed		O
with		O
the		O
requisite		O
2		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		O
substituted		B-MODIFIER
ethylamines		B-IUPAC
to		O
give		O
the		O
intermediate		O
thioureas		O
(		O
2b		O
-		O
d		O
)		O
.		O
However		O
,		O
similar		O
condensation		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
14		I-IUPAC
-		I-IUPAC
iododaunorubicin		I-IUPAC
with		O
thiols		O
invariably		O
led		O
to		O
a		O
redox		O
reaction		O
,		O
with		O
the		O
formation		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
daunorubicin		I-IUPAC
and		O
disulfides		O
.		O
This		O
prodrug		O
strategy		O
may		O
be		O
generally		O
useful		O
for		O
introducing		O
dianionic		O
phosphates		O
and		O
phosphonates		O
into		O
cells		O
.		O
Three		O
prodrugs		O
of		O
AELs		O
(		O
proAELs		O
)		O
have		O
been		O
synthesized		O
and		O
four		O
liposome		O
systems		O
,		O
consisting		O
of		O
these		O
proAELs		O
,		O
were		O
investigated		O
for		O
enzymatic		O
degradation		O
by		O
secretory		O
phospholipase		O
A		O
(		O
2		O
)		O
(		O
sPLA		O
(		O
2		O
)		O
)		O
,		O
resulting		O
in		O
the		O
release		O
of		O
AELs		O
.		O
A		O
new		O
class		O
of		O
5		B-PARTIUPAC
-		I-PARTIUPAC
halo		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
alkoxy		I-PARTIUPAC
(		O
or		O
azido		B-PARTIUPAC
)		O
-		B-PARTIUPAC
5,6		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
azido		I-PARTIUPAC
-		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
deoxythymidines		I-PARTIUPAC
was		O
investigated		O
as		O
potential		O
anti		O
-		O
AIDS		O
drugs		O
.		O
Although		O
without		O
significant		O
antiviral		O
activity		O
in		O
cell		O
cultures		O
,		O
the		O
2		B-IUPAC
-		I-IUPAC
aminopurines		I-IUPAC
(		O
13		O
,		O
14-16		O
,		O
26-29		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
alkoxypurines		I-IUPAC
(		O
12		O
,		O
23-25		O
)		O
are		O
well		O
absorbed		O
after		O
oral		O
administration		O
to		O
mice		O
and		O
are		O
converted		O
efficiently		O
to		O
the		O
antiviral		O
guanine		O
derivatives		O
(		O
8		O
,		O
21		O
)		O
in		O
vivo		O
.		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
trifluoromethylphenyl		I-IUPAC
)		I-IUPAC
methan		I-IUPAC
one		I-IUPAC
(		O
8		O
)		O
,		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
methanone		I-IUPAC
(		O
13		O
)		O
,		O
and		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
phenylmethanone		I-IUPAC
(		O
14		O
)		O
are		O
very		O
potent		O
depressants		O
.		O
The		O
acylated		O
bis		B-IUPAC
-		I-IUPAC
catecholates		I-IUPAC
and		O
1,3		B-IUPAC
-		I-IUPAC
benzoxazine		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
were		O
coupled		O
with		O
ampicillin		O
or		O
amoxicillin		O
to		O
new		O
siderophore		O
aminoacylpenicillin		O
conjugates		O
.		O
On		O
the		O
other		O
hand		O
,		O
in		O
the		O
bioassay		O
systems		O
,		O
[		O
(		O
2S		O
,		O
3S		O
)		O
-		O
beta		O
-		O
Me		O
-		O
p		O
-		O
NO2Phe4		O
]		O
DPDPE		O
(		O
5		O
)		O
is		O
more		O
potent		O
than		O
DPDPE		O
and		O
8800		O
-		O
fold		O
selective		O
for		O
the		O
MVD		O
(		O
delta		O
receptor		O
)		O
vs		O
the		O
GPI		O
(		O
mu		O
receptor		O
)		O
,		O
making		O
it		O
the		O
most		O
highly		O
selective		O
ligand		O
in		O
this		O
series		O
for		O
the		O
delta		O
opioid		O
receptor		O
on		O
the		O
basis		O
of		O
these		O
bioassays		O
.		O
The		O
diesters		O
of		O
the		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
5,10		I-IUPAC
-		I-IUPAC
dideazapteroic		I-IUPAC
acid		I-IUPAC
types		O
so		O
obtained		O
were		O
saponified		O
and		O
then		O
readily		O
decarboxylated		O
by		O
heating		O
in		O
Me2SO		O
solution		O
to		O
provide		O
the		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5,10		I-IUPAC
-		I-IUPAC
dideazapteroic		I-IUPAC
acid		I-IUPAC
-		O
type		O
intermediates		O
.		O
Highly		O
potent		O
antagonists		O
,		O
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
isoquinolone		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
benzylcarboxamides		I-IUPAC
(		O
11		O
)		O
,		O
were		O
discovered		O
from		O
the		O
structure		O
-		O
activity		O
relationship		O
studies		O
on		O
the		O
isoquinolone		O
-		O
urea		O
lead		O
1a		O
.		O
These		O
compounds		O
showed		O
a		O
high		O
biological		O
activity		O
in		O
the		O
hydroosmotic		O
toad		O
bladder		O
assay		O
.		O
The		O
structure		O
-		O
activity		O
relationships		O
suggest		O
that		O
the		O
type		O
I		O
enzyme		O
has		O
preference		O
for		O
N		O
-		O
substituted		O
straight		O
alkyl		O
side		O
chains		O
of		O
four		O
to		O
five		O
carbon		O
atoms		O
.		O
Moreover		O
,		O
affinity		O
and		O
relative		O
efficacy		O
were		O
calculated		O
in		O
vitro		O
for		O
this		O
compound		O
at		O
M2		O
(		O
heart		O
force		O
and		O
rate		O
)		O
and		O
M3		O
(		O
ileum		O
and		O
bladder		O
)		O
receptors		O
in		O
order		O
to		O
investigate		O
muscarinic		O
receptor		O
heterogeneity		O
.		O
Similarly		O
,		O
H		O
-		O
Dmt		O
-		O
Tic		O
-		O
Gly		O
-		O
NH		O
-		O
Ph		O
(		O
5		O
)		O
had		O
nearly		O
equivalent		O
high		O
delta		O
-		O
agonism		O
(		O
pEC		O
(		O
50		O
)		O
,		O
8.52		O
)		O
and		O
mu		O
-		O
agonism		O
(		O
pEC		O
(		O
50		O
)		O
,		O
8.59		O
)		O
,		O
while		O
H		O
-		O
Dmt		O
-		O
Tic		O
-		O
Gly		O
-		O
NH		O
-		O
CH		O
(		O
2		O
)		O
-		O
Ph		O
(		O
6		O
)		O
whose		O
spacer		O
was		O
longer		O
by		O
a		O
single		O
methylene		O
group		O
exhibited		O
potent		O
delta		O
-		O
antagonism		O
(		O
pA		O
(		O
2		O
)		O
,		O
9.25		O
)		O
and		O
very		O
high		O
mu		O
-		O
agonism		O
(		O
pEC		O
(		O
50		O
)		O
,		O
8.57		O
)		O
.		O
22		B-IUPAC
-		I-IUPAC
Hydroxy		I-IUPAC
-		I-IUPAC
25		I-IUPAC
-		I-IUPAC
methylcholesterol		I-IUPAC
(		O
4a		O
)		O
and		O
25		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
22		I-IUPAC
-		I-IUPAC
hydroxycholesterol		I-IUPAC
(		O
15a		O
)		O
significantly		O
lowered		O
serum		O
cholesterol		O
levels		O
when		O
administered		O
ig		O
to		O
primates		O
;		O
25		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
22		I-IUPAC
-		I-IUPAC
hydroxycholesterol		I-IUPAC
(		O
15b		O
)		O
and		O
the		O
analogue		O
with		O
a		O
cyclopropyl		B-IUPAC
terminus		B-MODIFIER
,		O
20b		O
,		O
were		O
ineffective		O
.		O
These		O
results		O
,		O
together		O
with		O
previous		O
autoradiographic		O
brain		O
receptor		O
-		O
mapping		O
studies		O
that		O
indicate		O
similar		O
distribution		O
of		O
[		O
(		O
3		O
)		O
H		O
]		O
-		O
(		O
-		O
)		O
-		O
trans		O
-		O
H		O
(		O
2		O
)		O
-		O
PAT		O
sites		O
and		O
[		O
(		O
3		O
)		O
H		O
]		O
mepyramine		O
-		O
labeled		O
H		O
(		O
1		O
)		O
receptors		O
,		O
suggest		O
that		O
both		O
radioligands		O
label		O
the		O
same		O
histamine		O
H		O
(		O
1		O
)		O
receptors		O
in		O
rodent		O
brain		O
.		O
The		O
basic		O
ring		O
system		O
was		O
prepared		O
in		O
one		O
step		O
by		O
condensation		O
of		O
dilithiated		B-MODIFIER
(		B-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
aniline		I-IUPAC
(		O
3		O
)		O
with		O
(		B-IUPAC
tert		I-IUPAC
-		I-IUPAC
butoxycarbonyl		I-IUPAC
)		I-IUPAC
piperidinone		I-IUPAC
.		O
The		O
high		O
acidity		O
of		O
HOPO		O
ligands		O
and		O
the		O
much		O
lower		O
acidity		O
of		O
catechol		O
(		O
CAM		O
)		O
ligands		O
suggested		O
that		O
mixed		O
octadentate		O
(		O
CAM		O
-		O
HOPO		O
)		O
ligands		O
containing		O
one		O
or		O
two		O
1,2		O
-		O
HOPO		O
and		O
three		O
(		O
or		O
two		O
)		O
catechol		O
(		O
CAM		O
)		O
groups		O
might		O
be		O
as		O
effective		O
for		O
Pu		O
removal		O
[		O
fully		O
eight		O
-		O
coordinated		O
Pu		O
(		O
IV		O
)		O
complexes		O
formed		O
at		O
pH		O
&		O
gt		O
;		O
or		O
=		O
6		O
]		O
and		O
less		O
toxic		O
than		O
3,4,3		O
-		O
LIHOPO		O
.		O
Mitotic		O
blocking		O
appears		O
to		O
be		O
its		O
primary		O
mechanism		O
of		O
cytotoxic		O
activity		O
.		O
The		O
results		O
obtained		O
suggest		O
that		O
(		O
a		O
)		O
analogs		O
I		O
and		O
VI		O
are		O
potent		O
antagonists		O
of		O
the		O
pressor		O
response		O
of		O
angiotensin		O
II		O
in		O
normal		O
rat		O
,		O
VI		O
being		O
the		O
most		O
potent		O
antagonist		O
thus		O
far		O
synthesized		O
;		O
(		O
b		O
)		O
replacement		O
of		O
position		O
4		O
(		O
Tyr		O
)		O
with		O
MeTyr		O
or		O
position		O
5		O
and		O
/		O
or		O
8		O
(		O
Ile		O
)		O
with		O
Melle		O
in		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
isoleucine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
reduced		O
the		O
antagonist		O
activity		O
of		O
this		O
peptide		O
(		O
rabbit		O
aortic		O
strips		O
and		O
rats		O
)		O
,		O
indicating		O
that		O
steric		O
hindrance		O
imposed		O
due		O
to		O
N		O
-		O
methylation		O
in		O
positions		O
4		O
,		O
5		O
,		O
or		O
8		O
was		O
not		O
favorable		O
in		O
eliminating		O
the		O
initial		O
pressor		O
activity		O
or		O
prolonging		O
the		O
duration		O
of		O
action		O
of		O
[		O
Sar1		O
,		O
Ile8		O
]		O
angiotensin		O
II		O
without		O
reducing		O
its		O
antagonistic		O
properties		O
;		O
(		O
c		O
)		O
except		O
II		O
,		O
none		O
of		O
the		O
analogs		O
showed		O
any		O
enhanced		O
duration		O
of		O
action		O
,		O
suggesting		O
that		O
N		O
-		O
methylation		O
in		O
positions		O
5		O
or		O
8		O
did		O
not		O
afford		O
protection		O
against		O
proteolytic		O
enzymes		O
;		O
and		O
(		O
d		O
)		O
perfusion		O
studies		O
in		O
cat		O
adrenals		O
indicated		O
that		O
all		O
of		O
these		O
analogs		O
are		O
only		O
very		O
weak		O
secretagogues		O
.		O
Med.		O
Chem.		O
1998		O
,		O
41		O
)		O
.		O
Thus		O
,		O
a		O
large		O
,		O
nondiscriminating		O
hydrophobic		O
region		O
occurs		O
in		O
the		O
A3		O
receptor		O
in		O
proximity		O
to		O
the		O
N5		O
-		O
substituent		O
.		O
The		O
synthesis		O
and		O
structure		O
-		O
activity		O
relationships		O
(		O
SAR		O
)		O
of		O
1		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethylamine		I-IUPAC
derivatives		B-MODIFIER
5-8		O
designed		O
from		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dipropyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethoxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
ethylamine		I-IUPAC
hydrochloride		I-IUPAC
(		O
1		O
,		O
NE		O
-		O
100		O
)		O
are		O
presented		O
.		O
The		O
single		O
-		O
armed		O
aporphine		O
nitrogen		O
mustard		O
(		O
1e		O
)		O
was		O
also		O
active		O
in		O
P388		O
but		O
the		O
activity		O
was		O
less		O
than		O
that		O
observed		O
with		O
1b		O
-		O
d		O
.		O
Thus		O
,		O
a		O
series		O
of		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
propananilido		I-IUPAC
)		I-IUPAC
perhydroazepine		I-IUPAC
derivatives		B-MODIFIER
was		O
synthesized		O
and		O
pharmacologically		O
evaluated		O
in		O
mice		O
for		O
analgesic		O
activity		O
and		O
physical		O
-		O
dependence		O
capacity		O
.		O
Binding		O
studies		O
in		O
the		O
hippocampal		O
homogenates		O
revealed		O
that		O
[		O
125I		O
]		O
-		O
8		O
bound		O
to		O
a		O
single		O
high		O
-		O
affinity		O
site		O
(		O
Kd		O
=		O
0.38		O
+		O
/		O
-		O
0.03		O
nM		O
,		O
Bmax		O
=		O
310		O
+		O
/		O
-		O
20		O
fmol		O
/		O
mg		O
of		O
protein		O
)		O
.		O
The		O
results		O
suggest		O
that		O
the		O
dihydrofuran		O
ring		O
in		O
6a		O
and		O
6b		O
models		O
the		O
active		O
conformation		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
groups		B-MODIFIER
in		O
3		O
and		O
5		O
.		O
The		O
two		O
classes		O
of		O
inactivators		O
(		O
O'		B-IUPAC
-		I-IUPAC
epoxyalkyl		I-IUPAC
and		O
carboxy		B-IUPAC
-		I-IUPAC
epoxyalkyl		I-IUPAC
)		O
appear		O
to		O
operate		O
by		O
different		O
mechanisms		O
.		O
A		O
series		O
of		O
aldehydo		O
sugars		O
was		O
subjected		O
to		O
condensation		O
reactions		O
with		O
active		O
methylene		O
compounds		O
.		O
This		O
indicates		O
that		O
BTCP		O
is		O
the		O
most		O
selective		O
of		O
all		O
the		O
compounds		O
tested		O
for		O
sites		O
labeled		O
by		O
[		O
3H		O
]		O
BTCP		O
whereas		O
cocaine		O
is		O
most		O
selective		O
for		O
sites		O
labeled		O
by		O
[		O
3H		O
]		O
cocaine		O
.		O
N6		B-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
Nitrobenzyladenosine		I-IUPAC
and		O
its		O
2'		O
-		O
deoxy		O
analog		O
were		O
competitive		O
inhibitors		O
(		O
K1		O
65		O
,		O
22		O
MUM		O
)		O
.		O
4d		O
did		O
not		O
show		O
significant		O
affinity		O
for		O
AMPA		O
receptor		O
sites		O
,		O
but		O
turned		O
out		O
to		O
be		O
a		O
weak		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
aspartic		I-IUPAC
acid		I-IUPAC
(		O
NMDA		O
)		O
receptor		O
antagonist		O
.		O
In		O
each		O
case		O
,		O
the		O
activity		O
or		O
minimal		O
activity		O
of		O
each		O
compound		O
can		O
be		O
explained		O
on		O
the		O
basis		O
of		O
the		O
ability		O
of		O
one		O
or		O
more		O
accessible		O
conformer		O
of		O
each		O
molecule		O
to		O
clear		O
the		O
REV		O
calculated		O
here		O
.		O
Continuing		O
studies		O
on		O
the		O
chemical		O
modification		O
of		O
the		O
previously		O
reported		O
novel		O
tripeptide		O
SP		O
antagonist		O
,		O
N		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyloxycarbonyl		I-IUPAC
)		I-IUPAC
glutaminyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N1		I-IUPAC
-		I-IUPAC
formyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
tryptophyl		I-IUPAC
]		I-IUPAC
phenylalanine		I-IUPAC
benzyl		I-IUPAC
ester		I-IUPAC
[		O
Boc		O
-		O
Gln		O
-		O
D		O
-		O
Trp		O
-		O
(		O
CHO		O
)		O
-		O
Phe		O
-		O
OBzl		O
(		O
1		O
)		O
]		O
,		O
are		O
described		O
herein		O
.		O
carinii		O
or		O
T		O
.		O
A		O
surprising		O
degree		O
of		O
conformational		O
similarity		O
has		O
been		O
observed		O
for		O
the		O
peptide		O
backbone		O
.		O
Ep		O
.		O
The		O
most		O
active		O
compounds		O
were		O
found		O
in		O
the		O
hydroxamic		O
derivatives		O
of		O
cyclohexane		O
series		O
;		O
within		O
this		O
series		O
of		O
derivatives		O
a		O
marked		O
increase		O
of		O
potency		O
was		O
caused		O
by		O
alkylation		O
of		O
the		O
amidic		O
nitrogen		O
with		O
a		O
methyl		B-IUPAC
or		O
ethyl		B-IUPAC
group		B-MODIFIER
.		O
Compound		O
8		O
,		O
in		O
which		O
the		O
acidic		O
NH		O
group		O
is		O
in		O
the		O
same		O
region		O
of		O
space		O
as		O
that		O
in		O
1		O
,		O
although		O
the		O
aminosulfonyl		B-IUPAC
group		B-MODIFIER
is		O
reversed		O
with		O
respect		O
to		O
the		O
aromatic		O
ring		O
,		O
showed		O
poor		O
PNMT		O
affinity		O
and		O
modest		O
alpha		O
2		O
-		O
adrenoceptor		O
affinity		O
(		O
PNMT		O
Ki		O
=		O
330		O
microM		O
,		O
alpha		O
2		O
Ki		O
=		O
18		O
microM		O
,		O
selectivity		O
=		O
0.055		O
)		O
.		O
They		O
were		O
similar		O
in		O
potency		O
in		O
blocking		O
CAR		O
with		O
AB50		O
values		O
of		O
39		O
,		O
32		O
,		O
and		O
42		O
mg		O
/		O
kg		O
,		O
respectively		O
.		O
Others		O
were		O
specific		O
inhibitors		O
for		O
calpain		O
I		O
(		O
e.g.		O
,		O
73		O
)		O
or		O
calpain		O
II		O
(		O
e.g.		O
,		O
18		O
,		O
19		O
,		O
33		O
,		O
35		O
,		O
56		O
)		O
.		O
(		B-PARTIUPAC
Pivaloyloxy		I-PARTIUPAC
)		I-PARTIUPAC
methyl		I-PARTIUPAC
and		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cyclohexyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
esters		I-IUPAC
of		O
3		O
and		O
4		O
showed		O
marked		O
increases		O
in		O
oral		O
bioavailability		O
which		O
significantly		O
potentiated		O
the		O
inhibitory		O
effect		O
of		O
the		O
parent		O
compounds		O
on		O
AII		O
-		O
induced		O
pressor		O
response		O
.		O
Spiropiperidines		O
with		O
no		O
or		O
small		O
N		O
-		O
substituents		O
(		O
H		O
,		O
Me		O
,		O
Et		O
)		O
exert		O
very		O
low		O
affinity		O
for		O
both		O
sigma		O
1		O
and		O
sigma		O
2		O
binding		O
sites		O
(		O
IC50		O
(		O
sigma		O
1		O
,		O
sigma		O
2		O
)		O
&		O
gt		O
;		O
100		O
nM		O
)		O
,		O
whereas		O
medium		O
-		O
sized		O
substituents		O
(		O
e.g.		O
,		O
Pr		O
,		O
Bu		O
,		O
Ph		O
(		O
CH2		O
)		O
2		O
)		O
result		O
in		O
potent		O
,		O
but		O
unselective		O
compounds		O
(		O
IC50		O
(		O
sigma		O
1		O
,		O
sigma		O
2		O
)		O
=		O
2-5		O
nM		O
)		O
.		O
Analogues		O
of		O
methotrexate		O
(		O
MTX		O
)		O
and		O
aminopterin		O
(		O
AMT		O
)		O
modified		O
at		O
the		O
gamma		O
-		O
position		O
of		O
the		O
glutamate		O
side		O
chain		O
were		O
synthesized		O
and		O
evaluated		O
as		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
inhibitors		O
and		O
tumor		O
cell		O
growth		O
inhibitors		O
.		O
Evaluation		O
of		O
physical		O
-		O
dependence		O
capacity		O
of		O
the		O
most		O
potent		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
propananilido		I-IUPAC
)		I-IUPAC
perhydroazepines		I-IUPAC
reveals		O
no		O
significant		O
difference		O
for		O
these		O
compounds		O
as		O
compared		O
with		O
morphine		O
.		O
Structure		O
-		O
activity		O
relationships		O
were		O
evaluated		O
where		O
PAF		O
antagonist		O
activity		O
was		O
measured		O
in		O
vitro		O
by		O
determining		O
the		O
concentration		O
of		O
compound		O
(		O
IC50		O
)		O
required		O
to		O
inhibit		O
the		O
PAF		O
-		O
induced		O
aggregation		O
of		O
rabbit		O
washed		O
platelets		O
and		O
in		O
vivo		O
by		O
determining		O
the		O
oral		O
dose		O
(		O
ED50		O
)		O
which		O
protected		O
mice		O
from		O
a		O
lethal		O
injection		O
of		O
PAF		O
.		O
3,4		B-IUPAC
-		I-IUPAC
Dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
5,7		I-IUPAC
-		I-IUPAC
difluoro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzoxazolyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phthalazineacetic		I-IUPAC
acid		I-IUPAC
(		O
124		O
)		O
was		O
the		O
best		O
of		O
the		O
benzoxazole		O
series		O
(		O
IC50		O
=		O
3.2		O
x		O
10		O
(		O
-		O
9		O
)		O
M		O
)		O
;		O
it		O
suppressed		O
accumulation		O
of		O
sorbitol		O
in		O
rat		O
sciatic		O
nerve		O
by		O
78%		O
at		O
an		O
oral		O
dose		O
of		O
10		O
mg		O
/		O
kg		O
.		O
Reaction		O
of		O
3		O
with		O
ammonia		O
gave		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromovinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxycytidine		I-IUPAC
(		O
1		O
)		O
,		O
the		O
overall		O
yield		O
from		O
2		O
being		O
60%		O
.		O
This		O
structure		O
class		O
is		O
characterized		O
by		O
the		O
boat		O
conformation		O
of		O
the		O
tropane		O
ring		O
and		O
the		O
orientation		O
of		O
the		O
additional		O
bridge		O
(		O
and		O
therefore		O
of		O
the		O
nitrogen		O
lone		O
pair		O
)		O
together		O
with		O
the		O
unusual		O
placement		O
of		O
the		O
aromatic		O
moiety		O
.		O
(		O
2S		O
)		O
-		O
1		O
,		O
which		O
was		O
metabolized		O
to		O
2		O
to		O
a		O
greater		O
extent		O
than		O
(		O
2R		O
)		O
-		O
1		O
,		O
showed		O
no		O
stereoselectivity		O
,		O
affording		O
about		O
equal		O
amounts		O
of		O
(		O
2S		O
,		O
2		O
"		O
S		O
)		O
-		O
2		O
and		O
(		O
2S		O
,		O
2		O
"		O
R		O
)		O
-		O
2		O
.		O
As		O
an		O
inhibitor		O
of		O
Tg		O
DHFR		O
,		O
28		O
had		O
an		O
IC		O
(		O
50		O
)		O
of		O
5.5		O
nM		O
(		O
510		O
-		O
fold		O
lower		O
than		O
that		O
of		O
TMP		O
and		O
similar		O
to		O
that		O
of		O
PTX		O
)		O
and		O
an		O
SI		O
value		O
of		O
120		O
(		O
2		O
-		O
fold		O
better		O
than		O
TMP		O
and		O
vastly		O
superior		O
to		O
PTX		O
)		O
.		O
The		O
biological		O
data		O
indicate		O
strongly		O
that		O
the		O
aqueous		O
solubility		O
and		O
relatively		O
high		O
acidity		O
of		O
the		O
octadentate		O
HOPO		O
ligands		O
,		O
3,4,3		O
-		O
LIHOPO		O
and		O
DFO		O
-		O
HOPO		O
allow		O
them		O
to		O
form		O
complete		O
eight		O
-		O
coordinate		O
complexes		O
with		O
Pu		O
(		O
IV		O
)		O
ion		O
.		O
All		O
S		O
enantiomers		O
were		O
less		O
potent		O
than		O
the		O
R		O
ones		O
.		O
The		O
synthesis		O
of		O
10		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
analogues		B-MODIFIER
of		O
the		O
potent		O
antitumor		O
agent		O
8,10		B-IUPAC
-		I-IUPAC
dideazaminopterin		I-IUPAC
is		O
described		O
.		O
A		O
change		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
of		O
the		O
nonselective		O
3		O
to		O
H		O
[		O
23		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
hydroxynoraporphine		I-IUPAC
]		O
or		O
propyl		O
[		O
2		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
propylnoraporphine		I-IUPAC
]		O
increases		O
the		O
selectivity		O
for		O
5		O
-		O
HT1A		O
receptors		O
(		O
100		O
-		O
fold		O
)		O
and		O
dopamine		O
D2A		O
receptors		O
(		O
3		O
-		O
fold		O
)		O
,		O
respectively		O
.		O
Treatment		O
of		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromovinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
2		O
)		O
with		O
p		B-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
phosphorodichloridate		I-IUPAC
and		O
1,2,4		B-IUPAC
-		I-IUPAC
triazole		I-IUPAC
gave		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
br		I-IUPAC
o		I-IUPAC
movinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
3		O
)		O
.		O
These		O
data		O
suggest		O
that		O
radiolabeled		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothiophenes		I-IUPAC
are		O
potentially		O
useful		O
agents		O
for		O
cerebral		O
perfusion		O
imaging		O
by		O
single		O
-		O
photon		O
-		O
emission		O
computerized		O
tomography		O
(		O
SPECT		O
)		O
.		O
The		O
effects		O
of		O
hydrophobic		O
,		O
hydrogen		O
-		O
bonding		O
,		O
and		O
ionic		O
interactions		O
with		O
the		O
AT1		O
receptor		O
are		O
considered		O
.		O
These		O
analogs		O
were		O
examined		O
for		O
their		O
growth		O
inhibitory		O
effect		O
in		O
cultured		O
leukemic		O
cells		O
and		O
also		O
for		O
their		O
effect		O
on		O
adenosine		O
aminohydrolase		O
activity		O
.		O
Moreover		O
,		O
some		O
dihydropyrimidines		O
[		O
1q		O
[		O
R1		O
=		O
(		B-PARTIUPAC
CH2		I-PARTIUPAC
)		I-PARTIUPAC
2N		I-PARTIUPAC
(		I-PARTIUPAC
benzyl		I-PARTIUPAC
)		I-PARTIUPAC
(		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
phenylpropyl		I-PARTIUPAC
)		O
,		O
R2		O
=		O
CH2		B-IUPAC
(		I-IUPAC
cyclopropyl		I-IUPAC
)		I-IUPAC
,		O
X		O
=		O
0		O
-		O
NO2		O
]		O
,		O
1s		O
,		O
and		O
1t		O
]		O
were		O
weaker		O
in		O
blocking		O
atrioventricular		O
conduction		O
in		O
anesthetized		O
open		O
-		O
chest		O
dogs		O
and		O
less		O
toxic		O
than		O
the		O
dihydropyridines		O
.		O
(		O
S		O
)		O
-		O
(		O
-		O
)		O
-		O
7		O
was		O
the		O
most		O
potent		O
of		O
the		O
two		O
enantiomers		O
,		O
confirming		O
the		O
stereospecificity		O
of		O
the		O
interaction		O
with		O
alpha2		O
-		O
adrenoreceptors		O
.		O
Similar		O
relative		O
orders		O
of		O
potencies		O
are		O
also		O
found		O
in		O
the		O
other		O
two		O
bioassays		O
.		O
Compound		O
4a		O
was		O
obtained		O
in		O
four		O
steps		O
starting		O
with		O
two		O
successive		O
brominations		O
of		O
2		B-IUPAC
-		I-IUPAC
acetylfuran		I-IUPAC
first		O
with		O
N		B-IUPAC
-		I-IUPAC
bromosuccinimide		I-IUPAC
,		O
and		O
second		O
with		O
bromine		O
to		O
form		O
alpha		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
bromofuran		I-IUPAC
(		O
2		O
)		O
in		O
a		O
moderate		O
yield		O
.		O
Biological		O
studies		O
indicated		O
that		O
the		O
target		O
compounds		O
were		O
less		O
active		O
than		O
1		O
and		O
3		O
.		O
Carbocyclic		O
thymidine		O
(		O
carba		O
-		O
T		O
,		O
13		O
)		O
was		O
used		O
as		O
a		O
reference		O
,		O
flexible		O
carbocyclic		O
nucleoside		O
.		O
Three		O
compounds		O
(		O
5j		O
-		O
l		O
)		O
were		O
tested		O
for		O
antiproliferative		O
activity		O
against		O
human		O
tumor		O
cells		O
in		O
culture		O
.		O
The		O
results		O
obtained		O
were		O
as		O
follows		O
:		O
greater		O
than		O
62		O
,		O
84		O
,		O
9		O
,		O
333		O
,		O
21		O
,		O
and		O
5		O
,		O
respectively		O
.		O
The		O
kinetic		O
parameters		O
of		O
the		O
HLE		O
inhibition		O
were		O
determined		O
.		O
A		O
different		O
kinetic		O
assay		O
(		O
Ashani		O
,		O
Y		O
.		O
By		O
the		O
use		O
of		O
space		O
-		O
filling		O
models		O
,		O
a		O
novel		O
compound		O
,		O
6		B-IUPAC
-		I-IUPAC
carbamylmethyl		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
H		I-IUPAC
-		I-IUPAC
cyclopenta		I-IUPAC
[		I-IUPAC
f		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
was		O
devised		O
which		O
would		O
be		O
expected		O
to		O
hydrogen		O
bond		O
specifically		O
to		O
GC		O
pairs		O
in		O
the		O
major		O
groove		O
of		O
the		O
double		O
helix		O
such		O
that		O
(		O
i		O
)		O
the		O
amino		B-IUPAC
group		B-MODIFIER
of		O
the		O
cytosine		O
molecule		O
donates		O
a		O
hydrogen		O
bond		O
to		O
the		O
C		O
-		O
3		O
carbonyl		O
of		O
the		O
isoquinoline		O
moiety		O
and		O
(		O
ii		O
)		O
the		O
amide		O
proton		O
of		O
the		O
side		O
chain		O
donates		O
a		O
hydrogen		O
bond		O
to		O
the		O
N		O
-		O
7		O
of		O
guanine		O
.		O
However		O
,		O
only		O
those		O
sterols		O
with		O
a		O
modified		O
side		O
chain		O
terminus		O
were		O
effective		O
suppressors		O
of		O
liver		O
reductase		O
when		O
administered		O
ig		O
to		O
rats		O
.		O
The		O
preliminary		O
PET		O
experiments		O
in		O
baboons		O
with		O
[		O
18F		O
]		O
F		O
-		O
A		O
-		O
85380		O
show		O
an		O
accumulation		O
of		O
the		O
radiotracer		O
in		O
the		O
brain		O
within		O
60		O
min		O
.		O
The		O
anticonvulsant		O
activity		O
of		O
diphenylhydantoin		O
(		O
DPH		O
or		O
phenytoin		O
)		O
is		O
consistent		O
with		O
its		O
actions		O
on		O
the		O
neuronal		O
voltage		O
-		O
dependent		O
sodium		O
channel		O
.		O
In		O
general		O
,		O
the		O
antiproliferative		O
activity		O
correlated		O
with		O
inhibition		O
of		O
tubulin		O
polymerization		O
.		O
The		O
most		O
active		O
anti		O
-		O
DHBV		O
agent		O
(		O
9c		O
)		O
,		O
possessing		O
a		O
[		B-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
substituent		B-MODIFIER
at		O
N		O
-		O
1		O
,		O
exhibited		O
an		O
activity		O
(		O
EC		O
(		O
50		O
)		O
of		O
0.01-0.05		O
microg		O
/		O
mL		O
)		O
comparable		O
to		O
that		O
of		O
reference		O
compound		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
thiacytidine		I-IUPAC
(		O
3		O
-		O
TC		O
)		O
(		O
EC		O
(		O
50		O
)		O
=		O
0.01-0.05		O
microg		O
/		O
mL		O
)		O
.		O
Methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
isothiocyanatomethyl		I-IUPAC
)		I-IUPAC
thiazole		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamate		I-IUPAC
(		O
7		O
)		O
was		O
the		O
most		O
active		O
compound		O
in		O
this		O
screen		O
,		O
inhibiting		O
the		O
growth		O
of		O
L1210		O
leukemic		O
cells		O
with		O
an		O
IC50		O
=		O
3.2		O
microM		O
.		O
The		O
high		O
specific		O
activity		O
one		O
-		O
step		O
radiolabeling		O
preparation		O
and		O
high		O
selectivity		O
of		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
for		O
SERT		O
support		O
its		O
candidacy		O
as		O
a		O
radioligand		O
for		O
mapping		O
brain		O
SERT		O
sites		O
.		O
We		O
therefore		O
concluded		O
that		O
target		O
cysteines		O
in		O
the		O
hormone		O
-		O
binding		O
site		O
were		O
not		O
in		O
direct		O
contact		O
with		O
the		O
steroid		O
but		O
probably		O
in		O
the		O
immediate		O
neighborhood		O
of		O
the		O
D		O
ring		O
of		O
the		O
bound		O
steroid		O
.		O
The		O
absolute		O
configuration		O
of		O
the		O
respective		O
(		O
R		O
)		O
-		O
and		O
(		O
S		O
)		O
-		O
enantiomers		O
was		O
deduced		O
from		O
X		O
-		O
ray		O
crystallography		O
of		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
isopropylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
,		O
(		O
R		O
)		O
-		O
9a		O
.		O
Cell		O
culture		O
toxicity		O
reversal		O
studies		O
and		O
enzyme		O
inhibition		O
tests		O
showed		O
that		O
1		O
was		O
cytotoxic		O
but		O
not		O
by		O
the		O
mechanism		O
of		O
the		O
dihydrofolate		O
reductase		O
inhibitor		O
aminopterin		O
.		O
In		O
the		O
presence		O
of		O
carboxylate		O
esterase		O
,		O
however		O
,		O
it		O
was		O
degraded		O
,		O
in		O
a		O
concentration		O
-		O
dependent		O
manner		O
,		O
to		O
FdUMP		O
.		O
The		O
condensation		O
of		O
3		B-IUPAC
-		I-IUPAC
aminopyrazole		I-IUPAC
with		O
symmetrical		O
beta		O
-		O
diketones		O
(		O
acetylacetone		O
,		O
heptane		B-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
,		O
etc		O
.		O
Particularly		O
noteworthy		O
was		O
3		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxybenzyl		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazole		I-IUPAC
(		O
71		O
,		O
IC50		O
1.4		O
nM		O
)		O
,		O
which		O
blocked		O
the		O
AII		O
pressor		O
response		O
in		O
conscious		O
rats		O
at		O
0.3		O
mg		O
/		O
kg		O
iv		O
with		O
a		O
duration		O
of		O
action		O
of		O
approximately		O
6		O
h		O
,		O
similar		O
to		O
that		O
of		O
DuP		O
753		O
.		O
These		O
data		O
suggest		O
that		O
the		O
site		O
of		O
action		O
of		O
1		O
is		O
inhibition		O
of		O
purine		O
de		O
novo		O
biosynthesis		O
.		O
Metalation		O
of		O
benzanilide		O
with		O
n		B-IUPAC
-		I-IUPAC
butyllithium		I-IUPAC
,		O
addition		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
cyclohexanone		I-IUPAC
,		O
and		O
acidification		O
afforded		O
a		O
mixture		O
of		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
spiro		I-IUPAC
[		I-IUPAC
cyclohexane		I-IUPAC
-		I-IUPAC
1,1		I-IUPAC
'		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
isobenzofuran		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
(		O
1a		O
,		O
b		O
)		O
,		O
which		O
were		O
separated		O
by		O
fractional		O
crystallization		O
.		O
The		O
broad		O
spectrum		O
excitatory		O
amino		O
acid		O
antagonist		O
activity		O
of		O
the		O
4		O
-		O
unsubstituted		O
analogue		O
21		O
(		O
KbNMDA		O
=		O
6.7		O
microM		O
,		O
KbAMPA		O
=		O
9.2		O
microM		O
)		O
and		O
the		O
glycine		O
/		O
NMDA		O
selectivity		O
of		O
the		O
other		O
3		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
derivatives		B-MODIFIER
allows		O
the		O
proposal		O
of		O
a		O
model		O
for		O
AMPA		O
receptor		O
binding		O
which		O
differs		O
from		O
the		O
glycine		O
binding		O
pharmacophore		O
in		O
that		O
there		O
is		O
bulk		O
intolerance		O
adjacent		O
to		O
the		O
4		O
-		O
position		O
.		O
albicans		O
WD		O
18-4		O
.		O
Certain		O
congeners		O
were		O
up		O
to		O
145		O
-		O
fold		O
more		O
active		O
at		O
A1		O
receptors		O
than		O
at		O
A2		O
receptors		O
.		O
Thus		O
,		O
the		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
aminopyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
piperidine		I-IUPAC
analogue		B-MODIFIER
15y		O
exhibiting		O
190		O
-		O
fold		O
selectivity		O
for		O
M		O
(		O
3		O
)		O
receptors		O
(		O
K		O
(		O
i		O
)		O
=		O
2.8		O
nM		O
)		O
over		O
M		O
(		O
2		O
)		O
receptors		O
(		O
K		O
(		O
i		O
)		O
=		O
530		O
nM		O
)		O
in		O
a		O
human		O
binding		O
assay		O
and		O
good		O
in		O
vitro		O
metabolic		O
stability		O
in		O
dog		O
and		O
human		O
hepatic		O
microsomes		O
was		O
identified		O
.		O
Various		O
derivatives		O
of		O
the		O
congeners		O
should		O
be		O
useful		O
as		O
receptor		O
probes		O
and		O
for		O
radioiodination		O
,		O
avidin		O
binding		O
,		O
and		O
preparation		O
of		O
affinity		O
columns		O
.		O
The		O
8		B-IUPAC
-		I-IUPAC
vinylchlorins		I-IUPAC
obtained		O
by		O
refluxing		O
the		O
related		O
vic		O
-		O
dihydroxybacteriochlorins		O
in		O
o		B-IUPAC
-		I-IUPAC
dichlorobenzene		I-IUPAC
were		O
individually		O
treated		O
with		O
dimethylacetylenedicarboxylate		B-IUPAC
(		O
DMAD		O
)		O
under		O
Diels		O
-		O
Alder		O
reaction		O
conditions		O
.		O
As		O
demonstrated		O
for		O
cyclo		O
[		O
21,29		O
]		O
[		O
D		O
-		O
Cys		O
(		O
21		O
)		O
Cys		O
(		O
29		O
)		O
]		O
-		O
uPA		O
(		O
21		O
)		O
(		O
-		O
)		O
(		O
30		O
)		O
,		O
the		O
achieved		O
peptide		O
modifications		O
maintained		O
receptor		O
binding		O
activity		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.04		O
microM		O
)		O
,		O
which		O
is		O
close		O
in		O
order		O
to		O
that		O
of		O
the		O
parent		O
protein		O
ligand		O
,		O
uPA		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.01		O
microM		O
)		O
.		O
A		O
molecular		O
model		O
of		O
the		O
27		O
-		O
A2B		O
receptor		O
complex		O
based		O
on		O
the		O
structure		O
of		O
rhodopsin		O
utilizing		O
a		O
"		O
cross		O
-		O
docking		O
"		O
procedure		O
was		O
developed		O
in		O
order		O
to		O
visualize		O
the		O
environment		O
of		O
the		O
ligand		O
binding		O
site		O
.		O
2		B-IUPAC
-		I-IUPAC
Aminoadipic		I-IUPAC
acid		I-IUPAC
(		O
3		O
)		O
,		O
which		O
shows		O
a		O
complex		O
excitatory		O
amino		O
acid		O
synaptic		O
pharmacology		O
,		O
was		O
an		O
agonist		O
at		O
mGlu6		O
as		O
well		O
as		O
mGlu2		O
.		O
Surprisingly		O
,		O
one		O
analog		O
with		O
D		O
-		O
stereochemistry		O
in		O
residue		O
3		O
,		O
the		O
(		O
2R		O
,		O
3R		O
)		O
-		O
MePhe3		O
analog		O
,		O
also		O
displays		O
high		O
affinity		O
for		O
the		O
delta		O
receptor		O
and		O
is		O
extraordinarily		O
selective		O
for		O
this		O
receptor		O
.		O
The		O
development		O
of		O
a		O
prostaglandin		O
PGF2		O
alpha		O
photoaffinity		O
probe		O
led		O
to		O
the		O
synthesis		O
and		O
biological		O
evaluation		O
of		O
azide		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
17		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
18,19,20		I-IUPAC
-		I-IUPAC
trinorprostaglandin		I-IUPAC
F2		I-IUPAC
alpha		I-IUPAC
and		O
16		B-IUPAC
-		I-IUPAC
phenoxy		I-IUPAC
-		I-IUPAC
17,18,19,20		I-IUPAC
-		I-IUPAC
tetranorprostaglandin		I-IUPAC
F2		I-IUPAC
alpha		I-IUPAC
derivatives		O
.		O
Because		O
of		O
the		O
susceptibility		O
to		O
acid		O
-		O
catalyzed		O
hydrolysis		O
of		O
these		O
tertiary		O
enamines		O
,		O
however		O
,		O
these		O
compounds		O
serve		O
only		O
as		O
model		O
compounds		O
for		O
their		O
structure		O
-		O
activity		O
evaluation		O
.		O
The		O
analog		O
was		O
found		O
to		O
be		O
a		O
potent		O
inhibitor		O
of		O
the		O
oxytocic		O
and		O
avian		O
vasodepressor		O
effects		O
of		O
oxytocin		O
(		O
pA2		O
values		O
of		O
7.43		O
and		O
8.30		O
,		O
respectively		O
)		O
but		O
was		O
only		O
a		O
weak		O
inhibitor		O
of		O
the		O
rat		O
pressor		O
effect		O
of		O
8		B-IUPAC
-		I-IUPAC
lysine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
.		O
The		O
two		O
most		O
active		O
members		O
of		O
this		O
series		O
,		O
39		O
and		O
63		O
,		O
were		O
active		O
against		O
the		O
gastrointestinal		O
nematodes		O
of		O
sheep		O
at		O
100		O
mg		O
/		O
kg		O
.		O
This		O
derivative		O
,		O
(		B-IUPAC
S		I-IUPAC
*		I-IUPAC
,		I-IUPAC
R		I-IUPAC
*		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
mercaptopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
leucyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
isoquinolinyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamine		I-IUPAC
,		O
was		O
evaluated		O
in		O
vivo		O
along		O
with		O
(		B-IUPAC
S		I-IUPAC
*		I-IUPAC
,		I-IUPAC
R		I-IUPAC
*		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
mercaptopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
leucyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
isoquinolinyl		I-IUPAC
]		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
methionine		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
for		O
antitumor		O
activity		O
in		O
an		O
athymic		O
mouse		O
model		O
implanted		O
ip		O
with		O
H		O
-		O
ras		O
-		O
transformed		O
rat		O
-		O
1		O
tumor		O
cells		O
.		O
Ring		O
closure		O
of		O
ethyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
aminopyrazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
with		O
sulfamoyl		O
chloride		O
gave		O
1,7		B-IUPAC
-		I-IUPAC
dihydropyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,2,6		I-IUPAC
]		I-IUPAC
thiadiazine		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
.		O
The		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
propananilido		I-IUPAC
)		I-IUPAC
perhydroazepines		I-IUPAC
having		O
1		O
-		O
substitutents		O
in		O
common		O
with		O
known		O
opiate		O
antagonists		O
failed		O
to		O
exhibit		O
antagonism		O
of		O
morphine		O
analgesia		O
.		O
Preliminary		O
indications		O
are		O
that		O
9		O
may		O
act		O
by		O
both		O
central		O
and		O
peripheral		O
mechanisms		O
.		O
The		O
anti		O
-		O
HIV		O
potency		O
of		O
purine		O
analogues		O
was		O
found		O
to		O
be		O
in		O
the		O
following		O
decreasing		O
order		O
:		O
2,6		B-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		B-IUPAC
-		I-IUPAC
chloroadenine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		B-IUPAC
-		I-IUPAC
fluoroadenine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
adenine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
guanine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2		B-IUPAC
-		I-IUPAC
fluoroadenine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
adenine		O
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
2,6		B-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
N6		B-IUPAC
-		I-IUPAC
methyladenine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
.		O
Affinity		O
labeling		O
was		O
directly		O
demonstrated		O
by		O
ethanol		O
-		O
resistant		O
binding		O
of		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
[		I-IUPAC
(		I-IUPAC
iodoacetamido		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
to		O
the		O
receptor		O
.		O
The		O
aforementioned		O
products		O
,		O
plus		O
two		O
related		O
phenylselena		O
derivatives		O
,		O
were		O
examined		O
for		O
in		O
vitro		O
growth		O
inhibition		O
,		O
in		O
vivo		O
antitumor		O
activity		O
,		O
and		O
,		O
where		O
appropriate		O
,		O
DNA		O
binding		O
.		O
CCK		O
-		O
B		O
and		O
CCK		O
-		O
A		O
binding		O
affinities		O
of		O
these		O
analogues		O
are		O
described		O
and		O
their		O
CCK		O
-		O
B		O
affinity		O
and		O
selectivity		O
rationalized		O
by		O
consideration		O
of		O
the		O
pK		O
(		O
a		O
)		O
values		O
,		O
charge		O
distribution		O
,		O
and		O
geometry		O
of		O
the		O
respective		O
acid		O
mimics		O
.		O
The		O
design		O
,		O
synthesis		O
,		O
and		O
pharmacological		O
properties		O
of		O
a		O
novel		O
type		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,5,6		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thiazolamine		I-IUPAC
with		O
dopaminergic		O
properties		O
are		O
described		O
.		O
falciparum		O
(		O
P		O
.		O
The		O
studies		O
suggest		O
that		O
the		O
nitrogen		O
lone		O
pair		O
orientation		O
found		O
in		O
the		O
piperazines		O
affords		O
the		O
strongest		O
binding		O
interaction		O
.		O
A		O
primary		O
action		O
of		O
the		O
compound		O
on		O
cyclooxygenase		O
is		O
excluded		O
,		O
as		O
a		O
stable		O
epoxymethano		O
analogue		O
of		O
prostaglandin		O
H2		O
does		O
not		O
reverse		O
the		O
inhibitory		O
effect		O
of		O
10a		O
.		O
A		O
series		O
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyphenethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryloxy		I-IUPAC
)		I-IUPAC
propan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ols		I-IUPAC
was		O
synthesized		O
together		O
with		O
several		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dimethoxyphenethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryloxy		I-IUPAC
)		I-IUPAC
propan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ols		I-IUPAC
.		O
Single		O
-		O
crystal		O
X		O
-		O
ray		O
analysis		O
of		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
picrate		I-IUPAC
confirmed		O
its		O
trans		O
configuration		O
and		O
provided		O
conformational		O
data		O
.		O
In		O
the		O
5		O
-		O
bromo		O
series		O
of		O
compounds		O
,		O
the		O
C		O
-		O
6		O
substituent		O
was		O
also		O
a		O
determinant		O
of		O
activity		O
where		O
6		O
-		O
OMe		O
and		O
6		O
-		O
OEt		O
substituents		O
exhibited		O
a		O
greater		O
potency		O
than		O
the		O
corresponding		O
6		O
-		O
i		O
-		O
PrO		O
,		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
octyloxy		I-IUPAC
)		I-IUPAC
,		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hexadecyloxy		I-IUPAC
)		I-IUPAC
,		O
and		O
6		B-IUPAC
-		I-IUPAC
azido		I-IUPAC
analogs		B-MODIFIER
.		O
For		O
1		B-PARTIUPAC
-		I-PARTIUPAC
cyclopropyl		I-PARTIUPAC
7		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2,6		I-PARTIUPAC
-		I-PARTIUPAC
dimethyl		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
pyridinyl		I-PARTIUPAC
)		I-PARTIUPAC
derivatives		B-MODIFIER
,		O
the		O
6		B-PARTIUPAC
-		I-PARTIUPAC
fluoro		I-PARTIUPAC
4a		O
,		O
8		B-PARTIUPAC
-		I-PARTIUPAC
fluoro		I-PARTIUPAC
10d		O
,		O
6,8		B-PARTIUPAC
-		I-PARTIUPAC
difluoro		I-PARTIUPAC
10b		O
,		O
and		O
5,6,8		B-PARTIUPAC
-		I-PARTIUPAC
trifluoro		I-PARTIUPAC
8		O
,		O
all		O
provided		O
equal		O
antibacterial		O
activity		O
against		O
Staphylococcus		O
aureus		O
ATCC		O
29213		O
.		O
It		O
is		O
concluded		O
that		O
homo		O
-		O
AMPA		O
(		O
8		O
)		O
is		O
likely		O
to		O
be		O
a		O
useful		O
tool		O
for		O
studies		O
of		O
the		O
pharmacology		O
and		O
physiological		O
role		O
of		O
mGlu6		O
.		O
A		O
number		O
of		O
17		B-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
alkyl		I-PARTIUPAC
/		I-PARTIUPAC
arylformamido		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
17		B-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
alkyl		I-PARTIUPAC
/		I-PARTIUPAC
aryl		I-PARTIUPAC
)		I-PARTIUPAC
alkyl		I-PARTIUPAC
/		I-PARTIUPAC
arylamido		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
oxo		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
aza		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
alpha		I-PARTIUPAC
-		O
steroids		B-MODIFIER
were		O
prepared		O
from		O
17		B-IUPAC
beta		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
azasteroids		I-IUPAC
and		O
evaluated		O
as		O
inhibitors		O
of		O
human		O
5		O
alpha		O
-		O
reductase		O
and		O
antagonists		O
of		O
the		O
androgen		O
receptor		O
.		O
rhodesiense		O
(		O
T		O
.		O
To		O
provide		O
targeted		O
accumulation		O
of		O
MGMT		O
inhibitors		O
in		O
tumor		O
tissue		O
as		O
well		O
as		O
tools		O
for		O
in		O
vivo		O
imaging		O
,		O
we		O
synthesized		O
iodinated		O
C		O
(		O
8		O
)		O
-		O
alkyl		O
-		O
linked		O
glucose		O
conjugates		O
of		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
purine		I-IUPAC
(		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothenyl		I-IUPAC
)		I-IUPAC
guanine		I-IUPAC
,		O
ITG		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
iodobenzyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
purine		I-IUPAC
(		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodobenzyl		I-IUPAC
)		I-IUPAC
guanine		I-IUPAC
,		O
IBG		O
)		O
.		O
The		O
fluorine		O
substituent		O
markedly		O
increases		O
the		O
phenolic		O
acidities		O
of		O
these		O
analogues		O
.		O
The		O
delta		O
Tm		O
values		O
for		O
the		O
5H		O
series		O
were		O
found		O
to		O
be		O
about		O
10		O
times		O
as		O
high		O
as		O
those		O
for		O
the		O
6H		O
compounds		O
.		O
[		B-IUPAC
1		I-IUPAC
]		I-IUPAC
Benzothieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridines		I-IUPAC
(		O
10a		O
-		O
c		O
,		O
11		O
,		O
12a		O
-		O
t		O
,		O
and		O
13a		O
,		O
b		O
)		O
and		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
[		I-IUPAC
1		I-IUPAC
]		I-IUPAC
benzothieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridines		I-IUPAC
(		O
3a		O
-		O
c		O
,		O
7		O
,		O
8a		O
-		O
c		O
,		O
and		O
9		O
)		O
were		O
synthesized		O
.		O
In		O
the		O
ODC		O
assay		O
,		O
all		O
thirteen		O
compounds		O
were		O
screened		O
.		O
Several		O
3beta		B-PARTIUPAC
-		I-PARTIUPAC
(		O
substituted		B-MODIFIER
phenyl		B-PARTIUPAC
)		O
-		B-PARTIUPAC
2beta		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
isoxazol		B-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
yl		I-PARTIUPAC
)		I-PARTIUPAC
tropanes		I-PARTIUPAC
(		O
3a		O
-		O
t		O
)		O
were		O
evaluated		O
for		O
their		O
ability		O
to		O
inhibit		O
radioligand		O
binding		O
at		O
the		O
DAT		O
,		O
5		O
-		O
HTT		O
,		O
and		O
NET		O
as		O
well		O
as		O
in		O
gross		O
observation		O
and		O
locomotor		O
activity		O
in		O
mice		O
and		O
in		O
rats		O
trained		O
to		O
discriminate		O
cocaine		O
.		O
The		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acids		I-IUPAC
4a		O
,		O
b		O
,		O
i		O
,		O
which		O
are		O
regioisosteric		O
analogues		O
of		O
3a		O
,		O
b		O
,		O
i		O
,		O
showed		O
negligible		O
interaction		O
with		O
AMPA		O
recognition		O
sites		O
.		O
No		O
affinity		O
for		O
NMDA		O
receptors		O
(		O
NMDA		O
-		O
sensitive		O
[		O
3H		O
]		O
glutamic		O
acid		O
binding		O
)		O
was		O
found		O
,		O
and		O
only		O
weak		O
affinity		O
in		O
[		O
3H		O
]		O
kainic		O
acid		O
binding		O
(		O
IC50		O
=		O
6.3		O
microM		O
)		O
was		O
detected		O
.		O
This		O
derivative		O
of		O
homofolate		O
may		O
be		O
responsible		O
for		O
its		O
inhibition		O
of		O
purine		O
biosynthesis		O
in		O
Sarcoma		O
180		O
cells		O
.		O
The		O
compounds		O
were		O
equally		O
active		O
after		O
oral		O
and		O
subcutaneous		O
administration		O
and		O
showed		O
a		O
long		O
duration		O
of		O
action		O
(		O
&		O
gt		O
;		O
24		O
h		O
)		O
.		O
These		O
analogues		O
of		O
vasotocin		O
are		O
the		O
most		O
potent		O
that		O
have		O
been		O
synthesized		O
to		O
date		O
,		O
and		O
they		O
should		O
serve		O
as		O
useful		O
probes		O
in		O
the		O
isolation		O
and		O
characterization		O
of		O
vasotocin		O
receptors		O
in		O
toad		O
bladders		O
and		O
tissues		O
from		O
other		O
species		O
that		O
use		O
vasotocin		O
as		O
an		O
antidiuretic		O
/		O
pressor		O
principle		O
.		O
New		O
compounds		O
in		O
the		O
5		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
series		B-MODIFIER
were		O
prepared		O
by		O
alkylation		O
of		O
an		O
appropriate		O
N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
aminobenzoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
dialkyl		I-IUPAC
ester		I-IUPAC
or		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thenoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
diester		I-IUPAC
with		O
a		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deazapteridine		I-IUPAC
.		O
The		O
pharmacology		O
of		O
THHBADs		O
was		O
characterized		O
by		O
electrical		O
recordings		O
in		O
Xenopus		O
oocytes		O
expressing		O
rat		O
brain		O
NMDA		O
and		O
AMPA		O
receptors		O
.		O
Generally		O
poor		O
potency		O
at		O
the		O
glycine		O
site		O
is		O
observed		O
when		O
a		O
variety		O
of		O
electron		O
-		O
withdrawing		O
substituents		O
are		O
attached		O
to		O
the		O
3		O
-		O
position		O
of		O
3,4		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
quinolones		I-IUPAC
.		O
[		O
18F		O
]		O
4b		O
and		O
[		O
18F		O
]		O
4c		O
showed		O
lower		O
specific		O
binding		O
ratios		O
than		O
[		O
carbonyl		O
-		O
11C		O
]		O
4a		O
and		O
[		O
18F		O
]		O
4d		O
.		O
The		O
highest		O
cytotoxic		O
activity		O
was		O
observed		O
for		O
3		B-IUPAC
-		I-IUPAC
methylenefuranones		I-IUPAC
13d		O
,		O
e		O
bearing		O
benzyl		B-IUPAC
or		O
3,4		B-IUPAC
-		I-IUPAC
dimethoxyphenylmethyl		I-IUPAC
substituents		B-MODIFIER
at		O
position		O
5		O
,		O
with		O
IC		O
(		O
50		O
)		O
values		O
of		O
5.4		O
and		O
6.0		O
microM		O
,		O
respectively		O
.		O
Peptide		O
coupling		O
with		O
diethyl		O
L		O
-		O
glutamate		O
followed		O
by		O
ester		O
hydrolysis		O
at		O
room		O
temperature		O
afforded		O
the		O
new		O
5,10		B-IUPAC
-		I-IUPAC
dideazaaminopterin		I-IUPAC
analogues		B-MODIFIER
.		O
The		O
syntheses		O
start		O
either		O
from		O
the		O
corresponding		O
8		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinolines		I-IUPAC
or		O
from		O
the		O
corresponding		O
noncyclized		O
amino		O
alcohols		O
.		O
Compound		O
3		O
also		O
inhibited		O
the		O
growth		O
of		O
several		O
human		O
tumor		O
cell		O
lines		O
in		O
culture		O
with		O
GI50		O
&		O
lt		O
;		O
10		O
(		O
-		O
8		O
)		O
M		O
.		O
Anthelmintic		O
efficacies		O
of		O
a		O
series		O
of		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
methyl		B-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamates		I-IUPAC
were		O
compared		O
to		O
similarly		O
substituted		B-MODIFIER
benzimidazole		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamates		I-IUPAC
.		O
The		O
induction		O
of		O
7		B-IUPAC
-		I-IUPAC
ethoxycoumarin		I-IUPAC
deethylase		O
activity		O
in		O
the		O
microsomal		O
fraction		O
from		O
rat		O
liver		O
by		O
alpha		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
,		O
beta		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
methylcholanthrene		I-IUPAC
and		O
the		O
inhibition		O
of		O
these		O
activities		O
by		O
flavone		O
and		O
alpha		B-PARTIUPAC
-		I-PARTIUPAC
,		O
beta		B-PARTIUPAC
,		O
and		O
gamma		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
have		O
also		O
been		O
examined		O
.		O
Within		O
the		O
series		O
of		O
derivatives		O
submitted		O
to		O
investigation		O
,		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butylcarbamoyl		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
methylenedioxyphthalazin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
2H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
21		O
)		O
proved		O
to		O
be		O
the		O
most		O
active		O
compound		O
and		O
is		O
11		O
-		O
fold		O
more		O
potent		O
than		O
1		O
(		O
i.e.		O
,		O
ED50		O
3.25		O
micromol		O
/		O
kg		O
for		O
21		O
versus		O
ED50		O
35.8		O
micromol		O
/		O
kg		O
for		O
1		O
)		O
.		O
WB		O
4101		O
(		O
1		O
)		O
-		O
related		O
benzodioxanes		O
were		O
synthesized		O
by		O
replacing		O
the		O
ethylene		O
chain		O
separating		O
the		O
amine		O
and		O
the		O
phenoxy		O
units		O
of		O
1		O
with		O
a		O
cyclopentanol		B-IUPAC
moiety		I-IUPAC
,		O
a		O
feature		O
of		O
6		B-IUPAC
,		I-IUPAC
7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenoxycyclopentyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
meth		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylbenzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiophen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
5H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
that		O
was		O
reported		O
to		O
display		O
an		O
intriguing		O
selectivity		O
profile		O
at		O
alpha		O
(		O
1		O
)		O
-		O
adrenoreceptors		O
.		O
Reduction		O
of		O
the		O
acid		O
group		O
of		O
5		O
gave		O
the		O
first		O
nonacidic		O
ETA		O
antagonist		O
in		O
our		O
series		O
,		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzyloxyphenoxy		I-IUPAC
)		I-IUPAC
prop2		I-IUPAC
-		I-IUPAC
enol		I-IUPAC
6		O
with		O
an		O
IC50		O
of		O
20		O
microM		O
.		O
The		O
analogues		O
were		O
evaluated		O
(		O
1		O
)		O
.		O
The		O
results		O
establish		O
that		O
the		O
presence		O
of		O
an		O
imidazole		O
N		O
-		O
3		O
nitrogen		O
substituent		O
is		O
not		O
required		O
to		O
inhibit		O
the		O
monooxygenase		O
activity		O
measured		O
by		O
the		O
deethylation		O
of		O
7		B-IUPAC
-		I-IUPAC
ethoxycoumarin		I-IUPAC
.		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
Benzoyl		I-IUPAC
-		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
threo		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
was		O
converted		O
to		O
a		O
mixture		O
of		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methylidene		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
and		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
didehydro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
,		O
which		O
were		O
separated		O
.		O
In		O
the		O
present		O
series		O
of		O
compounds		O
,		O
both		O
full		O
and		O
partial		O
agonists		O
were		O
found		O
.		O
Reaction		O
of		O
33		O
and		O
34		O
with		O
HCO2H		O
led		O
to		O
guanine		O
analogues		O
15		O
and		O
17		O
.		O
The		O
brominated		O
primary		O
amines		O
4c		O
,		O
d		O
were		O
assayed		O
initially		O
for		O
activity		O
in		O
the		O
two		O
-		O
lever		O
drug		O
discrimination		O
(		O
DD		O
)		O
paradigm		O
in		O
rats		O
trained		O
to		O
discriminate		O
saline		O
from		O
LSD		O
tartrate		O
(		O
0		O
.		O
The		O
most		O
active		O
compounds		O
are		O
2		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
methyl		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxoethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethoxy		I-IUPAC
)		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
propenoic+		I-IUPAC
+		I-IUPAC
+		I-IUPAC
acid		I-IUPAC
(		O
4g		O
)		O
of		O
the		O
indolyl		O
series		O
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
methyl		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxoethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethoxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthalenecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
2a		O
)		O
or		O
the		O
naphthyl		B-IUPAC
series		B-MODIFIER
,		O
with		O
IC50		O
of		O
8		O
and		O
4.7		O
nM		O
respectively		O
,		O
in		O
the		O
receptor		O
binding		O
assay		O
using		O
intact		O
human		O
neutrophils		O
.		O
Replacement		O
with		O
a		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
imidazolidinon		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
reduced		O
binding		O
to		O
alpha		O
1		O
adrenoceptors		O
with		O
a		O
factor		O
of		O
four		O
,		O
while		O
affinities		O
for		O
5		O
-		O
HT2		O
and		O
D2		O
receptors		O
were		O
retained		O
,		O
compared		O
to		O
the		O
3		B-MODIFIER
-		I-MODIFIER
unsubstituted		I-MODIFIER
imidazolidinone		B-IUPAC
.		O
The		O
homoanalog		O
,		O
methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
isothiocyanatoethyl		I-IUPAC
)		I-IUPAC
thiazole		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamate		I-IUPAC
,		O
was		O
prepared		O
from		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
aminothiazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
.		O
Two		O
distinct		O
sets		O
of		O
signals		O
for		O
the		O
tomaymycin		O
molecule		O
are		O
present		O
in		O
the		O
proton		O
NMR		O
spectrum		O
of		O
the		O
tomaymycin		O
-		O
d		O
(		O
ATGCAT		O
)		O
2		O
duplex		O
adduct		O
.		O
casei		O
thymidylate		O
synthase		O
compared		O
to		O
PDDF		O
.		O
The		O
second		O
set		O
of		O
compounds		O
includes		O
some		O
N		B-IUPAC
-		I-IUPAC
phenylalkyl		I-IUPAC
derivatives		B-MODIFIER
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylamine		I-IUPAC
that		O
can		O
be		O
considered		O
to		O
be		O
open		O
-		O
chain		O
derivatives		O
of		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
1		B-IUPAC
-		I-IUPAC
arylpiperazines		I-IUPAC
.		O
Phosphorylation		O
and		O
deblocking		O
gave		O
the		O
D		O
-		O
and		O
L		O
-		O
enantiomers		O
of		O
myo		B-IUPAC
-		I-IUPAC
inositol		I-IUPAC
1,3,4		I-IUPAC
-		I-IUPAC
trisphosphate		I-IUPAC
.		O
Preparation		O
of		O
the		O
target		O
5		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
alkoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
benzyluracil		I-IUPAC
derivatives		B-MODIFIER
27-34		O
was		O
carried		O
out		O
by		O
acetylation		O
of		O
9-14		O
followed		O
by		O
Pd		O
-		O
catalyzed		O
hydrogenolysis		O
.		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Chromon		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
were		O
less		O
potent		O
than		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
.		O
Selectivity		O
of		O
the		O
new		O
analogues		O
for		O
cloned		O
human		O
A3		O
adenosine		O
receptors		O
was		O
determined		O
vs		O
radioligand		O
binding		O
at		O
rat		O
brain		O
A1		O
and		O
A2A		O
receptors		O
.		O
Characterization		O
via		O
elemental		O
,		O
IR		O
,		O
1H		O
NMR		O
,		O
and		O
13C		O
NMR		O
analyses		O
was		O
completed		O
for		O
these		O
heterocycles		O
.		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
Bromovinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
BVDU		O
)		O
when		O
similarly		O
treated		O
gave		O
the		O
corresponding		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromovinyl		I-IUPAC
)		I-IUPAC
compound		B-MODIFIER
7		O
.		O
Out		O
of		O
seven		O
natural		O
analogues		O
and		O
18		O
chemical		O
derivatives		O
of		O
AbA		O
,		O
several		O
were		O
shown		O
to		O
display		O
even		O
more		O
potent		O
Pgp		O
-		O
inhibitory		O
activity		O
.		O
The		O
structure		O
of		O
the		O
[		O
99mTc		O
]		O
TRODAT		O
-		O
1		O
complexes		O
was		O
deduced		O
using		O
nonradioactive		O
rhenium		O
as		O
a		O
surrogate		O
for		O
radioactive		O
technetium		O
complex		O
.		O
Although		O
71		O
was		O
active		O
orally		O
only		O
at		O
a		O
10		O
-		O
fold		O
higher		O
dose		O
level		O
,		O
good		O
oral		O
bioavailability		O
was		O
demonstrated		O
for		O
a		O
monoacidic		O
analogue		O
62		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
The		O
synthesis		O
of		O
certain		O
heteroarotinoids		O
has		O
been		O
achieved		O
,		O
namely		O
the		O
systems		O
(		B-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
thiochromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoic		I-IUPAC
acid		I-IUPAC
(		O
1a		O
)		O
,		O
ethyl		B-IUPAC
(		I-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
teterahydro		I-IUPAC
-		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
thiochromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoate		I-IUPAC
(		O
1b		O
)		O
,		O
(		B-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoic		I-IUPAC
acid		I-IUPAC
(		O
1c		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
phthalimidoethyl		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
thiochromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoate		I-IUPAC
(		O
1d		O
)		O
,		O
methyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
2a		O
)		O
,		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzyl		I-IUPAC
alcohol		I-IUPAC
(		O
2b		O
)		O
,		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzonitrile		I-IUPAC
(		O
2c		O
)		O
,		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chromanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzaldehyde		I-IUPAC
(		O
2d		O
)		O
,		O
methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
benzofuranyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
3a		O
)		O
,		O
and		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
benzofuranyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
3b		O
)		O
.		O
Among		O
the		O
25		O
cell		O
lines		O
in		O
the		O
National		O
Cancer		O
Institute		O
panel		O
for		O
which		O
data		O
were		O
confirmed		O
in		O
two		O
independent		O
experiments		O
,		O
the		O
IC50		O
for		O
at		O
least		O
two		O
of		O
these		O
compounds		O
was		O
&		O
lt		O
;		O
10		O
microM		O
against		O
17		O
cell		O
lines		O
(		O
68%		O
)		O
and		O
in		O
the		O
0		O
.		O
Various		O
5		O
-		O
substituents		O
were		O
introduced		O
via		O
palladium		O
-		O
catalyzed		O
carbonylation		O
of		O
N		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
3		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
trifluoromethanesulfonyloxy		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
.		O
Antagonistic		O
and		O
agonistic		O
properties		O
of		O
the		O
analogues		O
were		O
studied		O
using		O
an		O
in		O
vitro		O
functional		O
assay		O
with		O
hamster		O
tracheal		O
rings		O
.		O
Surprisingly		O
,		O
two		O
compounds		O
,		O
2		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
morpholino		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
dibenzofuranyl		I-IUPAC
-		I-IUPAC
chromen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
NU7427		O
,		O
32		O
{		O
38		O
}		O
)		O
and		O
the		O
2		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
morpholino		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
dibenzothiophenyl		I-IUPAC
-		I-IUPAC
chromen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
NU7441		O
,		O
32		O
{		O
26		O
}		O
)		O
were		O
excellent		O
inhibitors		O
(		O
IC50		O
vs		O
DNA		O
-		O
PK		O
=		O
40		O
and		O
13		O
nM		O
,		O
respectively		O
)		O
.		O
A		O
Horners		O
-		O
Emmons		O
condensation		O
with		O
this		O
aldehyde		O
then		O
produced		O
retinoic		O
acid		O
analogs		O
with		O
both		O
9Z		O
-		O
and		O
9Z		O
,		O
13Z		O
-		O
configurations		O
.		O
Two		O
analogues		O
,		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
naphthylthio		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
furo		I-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
5		O
)		O
and		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
phenylanilino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
furo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
11		O
)		O
showed		O
significant		O
selectivity		O
and		O
potency		O
for		O
pcDHFR		O
compared		O
to		O
trimethoprim		O
.		O
The		O
greater		O
potency		O
of		O
8		O
and		O
12		O
,		O
as		O
compared		O
to		O
the		O
parent		O
unsubstituted		O
analogues		O
exo		B-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
and		O
anti		B-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
benzonorbornene		I-IUPAC
(		O
4		O
and		O
5		O
,		O
respectively		O
)		O
,		O
indicates		O
the		O
presence		O
of		O
a		O
spatially		O
compact		O
hydrophilic		O
pocket		O
within		O
the		O
aromatic		O
ring		O
binding		O
region		O
of		O
the		O
active		O
site		O
of		O
the		O
enzyme		O
.		O
Two		O
novel		O
classical		O
antifolates		O
N		B-IUPAC
-		I-IUPAC
{		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4,7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
benzoyl		I-IUPAC
}		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
3		O
and		O
N		B-IUPAC
-		I-IUPAC
{		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4,7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
benzoyl		I-IUPAC
}		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
4		O
were		O
designed		O
,		O
synthesized		O
,		O
and		O
evaluated		O
as		O
antitumor		O
agents		O
.		O
However		O
,		O
this		O
was		O
not		O
the		O
case		O
when		O
the		O
cargo		O
fragments		O
were		O
negatively		O
charged		O
.		O
To		O
this		O
end		O
,		O
we		O
have		O
prepared		O
(		O
9		O
-		O
fluorenylmethoxycarbonyl		O
-		O
SO		O
(		O
3		O
)		O
H		O
)		O
(		O
3		O
)		O
-		O
insulin		O
(		O
(		O
FMS		O
)		O
(		O
3		O
)		O
-		O
insulin		O
)		O
,		O
a		O
derivative		O
having		O
three		O
9		O
-		O
fluorenylmethoxycarbonyl		O
-		O
SO		O
(		O
3		O
)		O
H		O
(		O
FMS		O
)		O
moieties		O
covalently		O
linked		O
to		O
the		O
three		O
amino		O
side		O
chains		O
of		O
insulin		O
.		O
The		O
size		O
of		O
the		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
arylmethyl		I-IUPAC
substituent		B-MODIFIER
had		O
direct		O
bearing		O
on		O
the		O
observed		O
cytotoxicity		O
in		O
CHO		O
-		O
MG		O
cells		O
.		O
carinii		O
,		O
Toxoplasma		O
gondii		O
,		O
and		O
rat		O
liver		O
.		O
The		O
highest		O
CNS		O
activity		O
was		O
achieved		O
when		O
pyroglutamic		O
acid		O
was		O
replaced		O
by		O
pyro		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoadipic		I-IUPAC
acid		I-IUPAC
at		O
the		O
N		O
-		O
terminus		O
[		O
pAad		O
-		O
Leu		O
-		O
Pro		O
-		O
NH2		O
,		O
1		O
(		O
RGH		O
2202		O
)		O
,		O
and		O
pAad		O
-		O
Nva		O
-		O
Pro		O
-		O
NH2		O
,		O
2		O
]		O
.		O
Compound		O
18		O
(		O
L		O
-		O
162,223		O
)		O
displayed		O
very		O
prolonged		O
AII		O
antagonism		O
in		O
the		O
rat		O
model		O
(		O
&		O
gt		O
;		O
24		O
h		O
at		O
1		O
mg		O
/		O
kg		O
iv		O
)		O
.		O
Compound		O
28		O
(		O
4		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
pyrimidinecarboxylic		I-IUPAC
acid		I-IUPAC
)		O
was		O
the		O
most		O
effective		O
positive		O
inotropic		O
agent		O
,		O
while		O
the		O
corresponding		O
methyl		O
ester		O
17		O
reduced		O
both		O
the		O
contractile		O
force		O
and		O
the		O
frequency		O
of		O
guinea		O
pig		O
atria		O
.		O
(		O
FMS		O
)		O
(		O
3		O
)		O
-		O
insulin		O
is		O
soluble		O
in		O
aqueous		O
buffers		O
at		O
neutral		O
pH		O
,		O
at		O
a		O
concentration		O
range		O
of		O
0.15-0.60		O
mM		O
,		O
and		O
has		O
about		O
1%		O
of		O
both		O
the		O
biological		O
potency		O
and		O
the		O
receptor		O
-		O
binding		O
affinity		O
of		O
the		O
native		O
hormone		O
.		O
To		O
establish		O
if		O
the		O
potent		O
antagonistic		O
effects		O
of		O
these		O
bicyclic		O
compounds		O
was		O
because		O
of		O
the		O
lactam		O
ring		O
or		O
merely		O
the		O
result		O
of		O
obtaining		O
an		O
optimal		O
degree		O
of		O
lipophilicity		O
of		O
the		O
side		O
chains		O
in		O
positions		O
4		O
and		O
8		O
,		O
we		O
synthesized		O
a		O
series		O
of		O
analogues		O
containing		O
neutral		O
and		O
/		O
or		O
charged		O
groups		O
on		O
these		O
side		O
chains		O
.		O
While		O
these		O
solubilized		O
pyrimido		B-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
analogues		B-MODIFIER
were		O
less		O
potent		O
than		O
the		O
NHMe		O
derivative		O
5c		O
in		O
the		O
isolated		O
enzyme		O
assay		O
,		O
some		O
were		O
considerably		O
superior		O
to		O
5c		O
(		O
and		O
among		O
the		O
most		O
potent		O
ever		O
reported		O
)		O
as		O
inhibitors		O
of		O
EGFR		O
autophosphorylation		O
in		O
cellular		O
assays		O
.		O
The		O
photoaffinity		O
and		O
biotinyl		O
analogues		O
had		O
a		O
rat		O
antidiuretic		O
activity		O
of		O
66		O
and		O
40		O
units		O
/		O
mg		O
,		O
respectively		O
.		O
In		O
this		O
regard		O
,		O
a		O
cytotoxicity		O
model		O
was		O
proposed		O
,		O
which		O
describes		O
a		O
hydrophobic		O
pocket		O
of		O
set		O
dimensions		O
adjacent		O
to		O
the		O
putative		O
PAT		O
polyamine		O
-		O
binding		O
site		O
.		O
Since		O
the		O
proximal		O
nitrogen		O
atom		O
of		O
the		O
piperazine		O
ring		O
is		O
redundant		O
for		O
biological		O
activity		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propylidene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
a		I-IUPAC
,		I-IUPAC
d		I-IUPAC
]		I-IUPAC
cycloh		I-IUPAC
eptene		I-IUPAC
and		O
its		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
derivative		B-MODIFIER
are		O
excellent		O
candidates		O
for		O
resolution		O
into		O
enantiomers		O
as		O
a		O
means		O
to		O
separate		O
antimuscarinic		O
and		O
antidopaminergic		O
activity		O
,		O
respectively		O
,		O
associated		O
with		O
only		O
a		O
single		O
stereoisomer		O
.		O
The		O
key		O
step		O
in		O
the		O
synthetic		O
route		O
to		O
12a		O
was		O
Wittig		O
condensation		O
of		O
the		O
tributylphosphorane		O
derived		O
from		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylpyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
7a		O
)		O
with		O
methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
propionylbenzoate		I-IUPAC
.		O
As		O
the		O
structure		O
of		O
the		O
polyamines		O
was		O
varied		O
,		O
their		O
binding		O
at		O
sigma		O
-		O
1		O
and		O
sigma		O
-		O
2		O
subtypes		O
showed		O
quite		O
different		O
and		O
in		O
some		O
cases		O
opposite		O
trends		O
,		O
supporting		O
the		O
belief		O
that		O
these		O
are		O
pharmacologically		O
distinct		O
entities		O
.		O
Substrate		O
and		O
inhibitor		O
properties		O
indicated		O
that		O
the		O
compounds		O
possessed		O
affinity		O
for		O
the		O
ATP		O
sites		O
of		O
the		O
muscle		O
(		O
M		O
)		O
,		O
kidney		O
(		O
K		O
)		O
,		O
and		O
liver		O
(		O
L		O
)		O
isozymes		O
of		O
rat		O
pyruvate		O
kinase		O
(		O
PK		O
)		O
,		O
of		O
E		O
.		O
Novel		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
amide		I-IUPAC
derivatives		B-MODIFIER
1		O
were		O
synthesized		O
and		O
tested		O
for		O
their		O
ability		O
to		O
inhibit		O
rabbit		O
small		O
intestinal		O
ACAT		O
(		O
acyl		O
-		O
CoA		O
:		O
cholesterol		O
acyltransferase		O
)		O
in		O
vitro		O
and		O
to		O
lower		O
serum		O
total		O
cholesterol		O
in		O
cholesterol		O
-		O
fed		O
rats		O
in		O
vivo		O
.		O
Replacement		O
of		O
the		O
ureido		O
moiety		O
of		O
the		O
lead		O
compound		O
with		O
hydroxyguanidine		O
provided		O
a		O
stable		O
cytotoxic		O
agent		O
.		O
Compounds		O
having		O
an		O
i		O
-		O
Pr		O
ester		O
substituent		O
acted		O
as		O
dual		O
cardioselective		O
calcium		O
channel		O
agonists		O
(		O
GPLA		O
)		O
/		O
smooth		O
muscle		O
-		O
selective		O
calcium		O
channel		O
antagonists		O
(		O
GPILSM		O
)		O
,		O
except		O
for		O
the		O
C		O
-		O
4		O
3		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
compound		B-MODIFIER
which		O
exhibited		O
an		O
antagonist		O
effect		O
on		O
both		O
GPLA		O
and		O
GPILSM		O
.		O
N		O
-		O
(		O
2		O
-		O
Naphthyl		O
)		O
glycine		O
hydrazide		O
analogues		B-MODIFIER
were		O
synthesized		O
and		O
tested		O
for		O
possible		O
in		O
vitro		O
antitubercular		O
activity		O
.		O
The		O
DTPA		O
-		O
conjugated		O
,		O
side		O
-		O
chain		O
-		O
protected		O
peptide		O
was		O
cleaved		O
from		O
the		O
resin		O
by		O
aminolysis		O
with		O
threoninol		O
,		O
side		O
-		O
chain		O
deprotected		O
with		O
trifluoroacetic		O
acid		O
,		O
and		O
purified		O
by		O
semipreparative		O
RP		O
-		O
HPLC		O
.		O
A		O
series		O
of		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalenes		I-IUPAC
(		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
aminotetralins		I-IUPAC
,		O
PATs		O
)		O
previously		O
was		O
found		O
to		O
modulate		O
tyrosine		O
hydroxylase		O
activity		O
and		O
dopamine		O
synthesis		O
in		O
rodent		O
forebrain		O
through		O
interaction		O
with		O
a		O
binding		O
site		O
labeled		O
by		O
[		O
(		O
3		O
)		O
H		O
]		O
-		O
(		O
-		O
)		O
-		O
(		O
1R		O
,		O
3S		O
)		O
-		O
trans		O
-		O
H		O
(		O
2		O
)		O
-		O
PAT		O
.		O
Thus		O
,		O
certain		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydronaphthalenes		I-IUPAC
appear		O
to		O
be		O
selective		O
probes		O
of		O
a		O
novel		O
receptor		O
type		O
that		O
mediates		O
sigma		O
-		O
like		O
neuromodulatory		O
activity		O
and		O
may		O
have		O
pharmacotherapeutic		O
utility		O
in		O
conditions		O
in		O
which		O
modulation		O
of		O
dopamine		O
function		O
is		O
important		O
.		O
A		O
new		O
class		O
of		O
histamine		O
analogues		O
characterized		O
by		O
a		O
3		B-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
diphenylpropyl		I-IUPAC
substituent		B-MODIFIER
at		O
the		O
2		O
-		O
position		O
of		O
the		O
imidazole		O
nucleus		O
has		O
been		O
prepared		O
outgoing		O
from		O
4,4		B-IUPAC
-		I-IUPAC
diphenylbutyronitrile		I-IUPAC
(		O
4b		O
)		O
via		O
cyclization		O
of		O
the		O
corresponding		O
methyl		O
imidate		O
5b		O
with		O
2		B-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phthalimido		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
acetate		I-IUPAC
or		O
2		B-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
butandiol		I-IUPAC
in		O
liquid		O
ammonia		O
,		O
followed		O
by		O
standard		O
reactions		O
.		O
A		O
synthesis		O
scheme		O
for		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxynucleosides		I-IUPAC
and		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methylidene		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
has		O
been		O
proposed		O
with		O
2		B-IUPAC
-		I-IUPAC
deoxyribose		I-IUPAC
as		O
the		O
starting		O
material		O
.		O
The		O
GABA		O
ratios		O
close		O
to		O
unity		O
exhibited		O
by		O
all		O
the		O
tested		O
compounds		O
on		O
each		O
BzR		O
subtype		O
were		O
predictive		O
of		O
an		O
efficacy		O
profile		O
typical		O
of		O
antagonists		O
.		O
Molecular		O
modeling		O
of		O
the		O
interaction		O
of		O
these		O
compounds		O
with		O
AChE		O
from		O
Torpedo		O
californica		O
showed		O
them		O
to		O
interact		O
as		O
truly		O
THA		O
-		O
huperzine		O
A		O
hybrids		O
:		O
the		O
4		B-IUPAC
-		I-IUPAC
aminoquinoline		I-IUPAC
subunit		B-MODIFIER
of		O
(		O
-		O
)		O
-		O
19		O
occupies		O
the		O
same		O
position		O
of		O
the		O
corresponding		O
subunit		O
in		O
THA		O
,		O
while		O
its		O
bicyclo		O
[		O
3.3.1		O
]		O
nonadiene		O
substructure		O
roughly		O
occupies		O
the		O
same		O
position		O
of		O
the		O
corresponding		O
substructure		O
in		O
(		O
-		O
)		O
-		O
huperzine		O
A		O
,		O
in		O
agreement		O
with		O
the		O
absolute		O
configurations		O
of		O
(		O
-		O
)		O
-		O
19		O
and		O
(		O
-		O
)		O
-		O
huperzine		O
A		O
.		O
The		O
active		O
enantiomers		O
both		O
of		O
the		O
cis		O
series		O
(		O
21a		O
,		O
21c		O
)		O
and		O
trans		O
series		O
(		O
16b		O
,		O
16d		O
)		O
were		O
found		O
to		O
have		O
all		O
R		O
configuration		O
at		O
the		O
C		O
-		O
2		O
and		O
R		O
or		O
S		O
configuration		O
at		O
the		O
C		O
-		O
1		O
,		O
while		O
in		O
the		O
classical		O
ACE		O
inhibitors		O
S		O
configuration		O
at		O
the		O
terminal		O
carboxylate		O
(		O
corresponding		O
to		O
the		O
C		O
-		O
1		O
of		O
our		O
compounds		O
)		O
is		O
strictly		O
required		O
for		O
activity		O
.		O
Molecular		O
interactions		O
between		O
RGD		O
peptides		O
and		O
integrins		O
are		O
known		O
to		O
mediate		O
many		O
biological		O
and		O
pathological		O
processes		O
.		O
The		O
affinity		O
of		O
10		O
and		O
13-17		O
for		O
guinea		O
-		O
pig		O
H		O
(		O
1		O
)		O
receptors		O
increased		O
20		O
-		O
to		O
100		O
-		O
fold		O
compared		O
with		O
1		O
.		O
In		O
the		O
5		O
-		O
substituted		O
series		O
(		O
R1		O
in		O
3		O
)		O
,		O
the		O
trans		O
isomers		O
were		O
found		O
to		O
possess		O
higher		O
levels		O
of		O
pharmacological		O
activity		O
then		O
the		O
corresponding		O
cis		O
isomers		O
.		O
Ten		O
heretofore		O
undescribed		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
chloroquinazoline		I-IUPAC
analogues		B-MODIFIER
of		O
trimetrexate		O
(		O
TMQ		O
)		O
and		O
piritrexim		O
(		O
PTX		O
)		O
were		O
synthesized		O
and		O
tested		O
as		O
inhibitors		O
of		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
from		O
rat		O
liver		O
,		O
Pneumocystis		O
carinii		O
,		O
and		O
Toxoplasma		O
gondii		O
.		O
In		O
comparison		O
,		O
the		O
ID50		O
value		O
for		O
trans		O
-		O
retinoic		O
acid		O
(		O
1		O
)		O
was		O
0.12		O
nmol		O
while		O
the		O
ID50		O
values		O
for		O
acids		O
7		O
and		O
9		O
,		O
namely		O
(		B-IUPAC
2Z		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
thiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoic		I-IUPAC
acid		I-IUPAC
and		O
(		B-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,2,4,4		I-IUPAC
-		I-IUPAC
tetramethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4,6		I-IUPAC
-		I-IUPAC
heptatrienoic		I-IUPAC
acid		I-IUPAC
,		O
respectively		O
,		O
were		O
about		O
3.5		O
nmol		O
.		O
3		B-IUPAC
-		I-IUPAC
Methoxy		I-IUPAC
-		I-IUPAC
9,11		I-IUPAC
-		I-IUPAC
seco		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
17beta		I-IUPAC
-		I-IUPAC
acetoxyestra		I-IUPAC
-		I-IUPAC
1,3,5		I-IUPAC
(		I-IUPAC
10		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trien		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
oic		I-IUPAC
acid		I-IUPAC
(		O
2		O
)		O
,		O
prepared		O
by		O
CrO3		O
oxidation		O
of		O
1		O
,		O
on		O
hydrogenolysis		O
gave		O
methyl		B-IUPAC
17beta		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
9,11		I-IUPAC
-		I-IUPAC
secoestra		I-IUPAC
-		I-IUPAC
1,3,5		I-IUPAC
(		I-IUPAC
10		I-IUPAC
)		I-IUPAC
-		I-IUPAC
triene		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
3		O
)		O
.		O
Cisplatin		O
was		O
more		O
efficacious		O
than		O
both		O
trans		O
-		O
[		O
PtCl2		O
(		O
NH3		O
)		O
(		O
pip		O
-		O
pip		O
)		O
]		O
x		O
HCl		O
and		O
trans		O
-		O
[		O
PtCl2		O
(		O
NBA		O
)		O
(		O
pip		O
-		O
pip		O
)		O
]		O
x		O
HCl		O
in		O
the		O
A2780		O
and		O
A2780cisR		O
tumor		O
xenograft		O
models		O
,		O
consistent		O
with		O
its		O
lower		O
IC50		O
values		O
in		O
A2780		O
cells		O
but		O
contrary		O
to		O
the		O
higher		O
IC50		O
values		O
in		O
A2780cisR		O
cells		O
.		O
These		O
results		O
establish		O
that		O
the		O
MAO		O
-		O
catalyzed		O
bioactivation		O
of		O
MPTP		O
leads		O
to		O
the		O
formation		O
of		O
a		O
variety		O
of		O
reactive		O
molecules		O
that		O
are		O
potentially		O
cytotoxic		O
to		O
nigrostriatal		O
cells		O
.		O
Substitution		O
of		O
propanoic		O
or		O
propenoic		O
acid		O
moieties		O
for		O
the		O
acidic		O
heterocyclic		O
units		O
of		O
these		O
compounds		O
gave		O
the		O
monocyclic		O
amino		O
acids		O
15-18		O
,		O
which		O
have		O
very		O
little		O
or		O
no		O
affinity		O
for		O
GABAA		O
receptor		O
sites		O
.		O
gondii		O
versus		O
rat		O
liver		O
DHFR		O
was		O
observed		O
with		O
five		O
compounds		O
,		O
the		O
best		O
combination		O
of		O
potency		O
and		O
selectivity		O
being		O
achieved		O
with		O
the		O
2		B-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
analogue		B-MODIFIER
5d		O
,		O
which		O
had		O
an		O
IC50		O
of		O
0.014		O
microM		O
and		O
a		O
selectivity		O
ratio		O
of		O
8.6		O
.		O
As		O
hybrids		O
between		O
tropanes		O
and		O
quinuclidines		O
,		O
these		O
tropaquinuclidines		O
represent		O
a		O
significant		O
structural		O
departure		O
from		O
many		O
of		O
the		O
other		O
classes		O
of		O
tropane		O
ligands		O
synthesized		O
to		O
date		O
.		O
The		O
diverse		O
binding		O
properties		O
of		O
these		O
compounds		O
at		O
the		O
DA		O
-		O
uptake		O
site		O
and		O
their		O
spectrum		O
of		O
inhibitory		O
activities		O
for		O
[		O
3H		O
]		O
DA		O
uptake		O
identifies		O
them		O
as		O
a		O
useful		O
base		O
for		O
the		O
development		O
of		O
subtype		O
selective		O
probes		O
at		O
this		O
site		O
.		O
The		O
esters		O
of		O
the		O
appropriate		O
4		B-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
(		O
benzoyl		B-PARTIUPAC
)		O
starting		O
materials		O
were		O
sequentially		O
alkylated		O
upon		O
nitrogen		O
,		O
first		O
with		O
a		O
propargyl		O
halide		O
and		O
then		O
with		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyquinazoline		I-IUPAC
hydrobromide		I-IUPAC
.		O
The		O
results		O
observed		O
for		O
the		O
t		O
-		O
Hpp1		O
and		O
c		O
-		O
Hpp1		O
analogues		O
are		O
particularly		O
significant		O
since		O
these		O
two		O
residues		O
have		O
little		O
accessible		O
conformational		O
space		O
in		O
common		O
.		O
Analogs		O
of		O
CVFM		O
(		O
a		O
known		O
nonsubstrate		O
farnesyltransferase		O
(		O
FT		O
)		O
inhibitor		O
derived		O
from		O
a		O
CA1A2X		O
sequence		O
where		O
C		O
is		O
cysteine		O
,		O
A		O
is		O
an		O
aliphatic		O
residue		O
,		O
and		O
X		O
is		O
any		O
residue		O
)		O
were		O
prepared		O
where		O
phenylalanine		O
was		O
replaced		O
by		O
(		B-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
dehydrophenylalanine		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
aminoindan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
,		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
Tic		O
)		O
,		O
and		O
indoline		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
.		O
A		O
series		O
of		O
2,3		B-IUPAC
-		I-IUPAC
diaryl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
analogues		B-MODIFIER
substituted		B-MODIFIER
at		O
position		O
4		O
of		O
2		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
with		O
a		O
hydroxy		B-IUPAC
or		O
pyrrolidinoethoxy		B-IUPAC
residue		B-MODIFIER
were		O
synthesized		O
as		O
models		O
for		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
triarylpropenones		I-IUPAC
constrained		O
in		O
the		O
s		O
-		O
trans		O
conformation		O
.		O
A		O
similar		O
transformation		O
of		O
the		O
aglycone		O
of		O
toyocamycin		O
(		O
4m		O
)		O
furnished		O
the		O
corresponding		O
aglycone		O
of		O
thiosangivamycin		O
(		O
6m		O
)		O
.		O
The		O
binding		O
ability		O
of		O
[		O
(		O
131		O
)		O
I		O
]		O
ITGG		O
,		O
[		O
(		O
131		O
)		O
]		O
IBGG		O
,		O
[		O
(		O
131		O
)		O
I		O
]		O
ITG		O
,		O
and		O
[		O
(		O
131		O
)		O
I		O
]		O
IBG		O
to		O
purified		O
MGMT		O
was		O
tested		O
.		O
Compound		O
(		O
-		O
)		O
-		O
1		O
exhibited		O
a		O
Ki		O
of		O
81		O
+		O
/		O
-		O
13		O
nM		O
at		O
sigma		O
receptors		O
[		O
[		O
3H		O
]		O
-		O
(		O
+		O
)		O
-		O
3		O
-		O
PPP		O
]		O
and		O
250		O
+		O
/		O
-		O
8		O
nM		O
(		O
[		O
3H		O
]		O
DTG		O
)		O
.		O
Synthesis		O
methodology		O
was		O
developed		O
for		O
compounds		O
combining		O
three		O
moieties		O
:		O
pyridin		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
or		O
6		B-IUPAC
-		I-IUPAC
chloropyridin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
and		O
their		O
4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
azido		I-IUPAC
analogues		B-MODIFIER
;		O
imidazolidine		B-IUPAC
,		O
4		B-IUPAC
-		I-IUPAC
imidazoline		I-IUPAC
or		O
4		B-IUPAC
-		I-IUPAC
thiazoline		I-IUPAC
;		O
and		O
N		B-MODIFIER
-		I-MODIFIER
unsubstituted		I-MODIFIER
imine		B-IUPAC
,		O
nitroimine		O
,		O
cyanoimine		O
,		O
or		O
nitromethylene		O
.		O
Cyclization		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chloroanilino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
aminomethylquinoline		I-IUPAC
(		O
3a		O
)		O
and		O
its		O
6		O
-		O
OCH3		O
derivative		O
with		O
paraformaldehyde		O
gave		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,9		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethyltetrahydropyrimido		I-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
quinoline		I-IUPAC
(		O
4a		O
)		O
and		O
the		O
9		O
-		O
OCH3		O
derivative		O
4b		O
.		O
The		O
E		O
-		O
isomer		O
16		O
was		O
more		O
reactive		O
than		O
Z		O
-		O
isomer		O
14		O
.		O
The		O
reaction		O
of		O
2,4		B-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
dinitroimidazole		I-IUPAC
(		O
2		O
)		O
with		O
chloroethanol		O
or		O
hydrochloric		O
acid		O
yielded		O
4		B-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
(		I-IUPAC
4		I-IUPAC
)		I-IUPAC
-		I-IUPAC
chloroimidazole		I-IUPAC
(		O
3		O
)		O
,		O
which		O
upon		O
reaction		O
with		O
ethylene		O
oxide		O
yielded		O
the		O
4		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
chloroimidazole		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ethanol		I-IUPAC
(		O
6		O
)		O
.		O
The		O
structure		O
-		O
activity		O
relationships		O
in		O
this		O
series		O
of		O
antagonists		O
indicate		O
that		O
the		O
(		O
R		O
)		O
-		O
configuration		O
at		O
the		O
axial		O
bond		O
and		O
the		O
stacking		O
(		O
or		O
stacking		O
-		O
like		O
)		O
conformation		O
between		O
the		O
two		O
phenyl		B-IUPAC
rings		B-MODIFIER
as		O
shown		O
in		O
1t		O
-		O
A		O
and		O
3a		O
-		O
A		O
are		O
essential		O
for		O
high		O
-		O
affinity		O
binding		O
and		O
suggest		O
that		O
the		O
amide		B-IUPAC
moiety		B-MODIFIER
functions		O
as		O
a		O
hydrogen		O
bond		O
acceptor		O
in		O
the		O
interaction		O
with		O
the		O
receptor		O
.		O
Whereas		O
compounds		O
4-6		O
and		O
8		O
did		O
not		O
exhibit		O
a		O
selective		O
antiviral		O
effect		O
,		O
compounds		O
1-3		O
and		O
7		O
proved		O
almost		O
as		O
active		O
as		O
the		O
reference		O
compound		O
BVDU		O
.		O
In		O
preliminary		O
in		O
vitro		O
(		O
RIF		O
tumor		O
cells		O
)		O
and		O
in		O
vivo		O
screening		O
(		O
C3H		O
/		O
HeJ		O
mice		O
bearing		O
RIF		O
tumors		O
)		O
,		O
some		O
of		O
these		O
compounds		O
were		O
found		O
to		O
be		O
quite		O
effective		O
.		O
r		O
.		O
In		O
addition		O
,		O
compound		O
37		O
inhibited		O
apomorphine		O
-		O
induced		O
climbing		O
behavior		O
much		O
more		O
potently		O
(		O
ED50		O
of		O
3.4		O
mg		O
/		O
kg		O
)		O
than		O
stereotyped		O
behavior		O
(		O
ED50		O
of		O
32.2		O
mg		O
/		O
kg		O
)		O
and		O
will		O
be		O
evaluated		O
further		O
.		O
The		O
ability		O
of		O
conjugates		O
of		O
peptides		O
and		O
5		B-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
or		O
5		B-IUPAC
-		I-IUPAC
fluoroorotic		I-IUPAC
acid		I-IUPAC
to		O
enter		O
Candida		O
albicans		O
was		O
investigated		O
.		O
With		O
a		O
novel		O
assay		O
using		O
isolated		O
ferret		O
detrusor		O
to		O
estimate		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptor		O
agonistic		O
activity		O
,		O
we		O
found		O
that		O
a		O
series		O
of		O
glycine		O
derivatives		O
of		O
ritodrine		O
,		O
a		O
beta		O
(		O
2		O
)		O
-		O
adrenoceptor		O
agonist		O
,		O
are		O
potent		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptor		O
agonists		O
,		O
with		O
excellent		O
selectivity		O
versus		O
beta		O
(		O
1		O
)		O
and		O
beta		O
(		O
2		O
)		O
subtypes		O
.		O
Rings		O
of		O
rat		O
aorta		O
were		O
used		O
as		O
a		O
"		O
negative		O
screen		O
"		O
for		O
the		O
test		O
antagonists		O
.		O
f		O
.		O
Selective		O
acetylation		O
at		O
the		O
primary		O
amine		O
position		O
of		O
6		O
,		O
to		O
give		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylbutyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxoethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
acetylamino		I-IUPAC
)		I-IUPAC
butan		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
olide		I-IUPAC
(		O
7		O
)		O
,		O
led		O
to		O
a		O
considerable		O
decrease		O
in		O
activity		O
.		O
The		O
synthesis		O
of		O
a		O
series		O
of		O
diaryl		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
prolylpyrrolidine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
R		I-IUPAC
,		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
phosphonates		I-IUPAC
with		O
different		O
substituents		O
on		O
the		O
aryl		O
rings		O
(		O
hydroxyl		B-IUPAC
,		O
methoxy		B-IUPAC
,		O
acylamino		B-IUPAC
,		O
sulfonylamino		B-IUPAC
,		O
ureyl		B-IUPAC
,		O
methoxycarbonyl		B-IUPAC
,		O
and		O
alkylaminocarbonyl		B-IUPAC
)		O
started		O
from		O
the		O
corresponding		O
phosphites		O
.		O
Bioassay		O
results		O
from		O
guinea		O
pig		O
ileum		O
and		O
mouse		O
vas		O
deferens		O
preparations		O
are		O
in		O
general		O
agreement		O
with		O
the		O
binding		O
results		O
;		O
however		O
some		O
potency		O
discrepancies		O
are		O
observed		O
.		O
1H		B-IUPAC
-		I-IUPAC
Benzimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamides		I-IUPAC
,		O
particularly		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
derivatives		B-MODIFIER
,		O
are		O
identified		O
as		O
a		O
class		O
of		O
potent		O
PARP		O
inhibitors		O
.		O
The		O
=		O
N		O
-		O
OH		O
substituent		O
of		O
the		O
pyrimidine		O
C		O
(		O
4		O
)		O
prevented		O
the		O
enzyme		O
-		O
catalyzed		O
release		O
from		O
the		O
C		O
(		O
5		O
)		O
of		O
Br		O
(		O
-		O
)		O
and		O
I		O
(		O
-		O
)		O
(		O
the		O
same		O
shown		O
previously		O
for		O
H		O
(		O
+		O
)		O
)		O
.		O
Compounds		O
9a		O
-		O
c		O
and		O
10a		O
,		O
b		O
,		O
possessing		O
1		B-IUPAC
-		I-IUPAC
hydroxyimidazole		I-IUPAC
as		O
the		O
terminal		O
acidic		O
function		O
,		O
were		O
devoid		O
of		O
activity		O
in		O
all		O
of		O
the		O
systems		O
tested		O
.		O
